<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004532.pub2" GROUP_ID="INFECTN" ID="987603070909375534" MERGED_FROM="" MODIFIED="2013-04-29 10:30:27 +0100" MODIFIED_BY="Anne-Marie Stephani" REVIEW_NO="PJUT" REVMAN_SUB_VERSION="5.2.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.3">
<COVER_SHEET MODIFIED="2013-04-29 09:48:14 +0100" MODIFIED_BY="Anne-Marie Stephani">
<TITLE>Routine surgery in addition to chemotherapy for treating spinal tuberculosis</TITLE>
<CONTACT>
<PERSON ID="19577" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Paul</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Jutte</LAST_NAME>
<SUFFIX/>
<POSITION>Orthopaedic Surgeon</POSITION>
<EMAIL_1>p.c.jutte@umcg.nl</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>University Medical Center Groningen</DEPARTMENT>
<ORGANISATION/>
<ADDRESS_1>Hanzeplein 1</ADDRESS_1>
<ADDRESS_2>PO Box 30.001</ADDRESS_2>
<CITY>Groningen</CITY>
<ZIP>9700 RB</ZIP>
<REGION/>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<PHONE_1>+31 503612802 ext. 55478</PHONE_1>
<PHONE_2/>
<FAX_1>+31 50361 1737</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2013-04-29 09:45:16 +0100" MODIFIED_BY="Anne-Marie Stephani">
<PERSON ID="19577" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Paul</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Jutte</LAST_NAME>
<SUFFIX/>
<POSITION>Orthopaedic Surgeon</POSITION>
<EMAIL_1>p.c.jutte@umcg.nl</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>University Medical Center Groningen</DEPARTMENT>
<ORGANISATION/>
<ADDRESS_1>Hanzeplein 1</ADDRESS_1>
<ADDRESS_2>PO Box 30.001</ADDRESS_2>
<CITY>Groningen</CITY>
<ZIP>9700 RB</ZIP>
<REGION/>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<PHONE_1>+31 503612802 ext. 55478</PHONE_1>
<PHONE_2/>
<FAX_1>+31 50361 1737</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="9ACFCFEE82E26AA201609AF9ED9D20A4" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Joke</FIRST_NAME>
<MIDDLE_INITIALS>H</MIDDLE_INITIALS>
<LAST_NAME>van Loenhout-Rooyackers</LAST_NAME>
<SUFFIX>MD, PhD</SUFFIX>
<POSITION>Pulmonologist</POSITION>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Tuberculosis</DEPARTMENT>
<ORGANISATION>GGD Regio Nijmegen (Public Health Office)</ORGANISATION>
<ADDRESS_1>PO Box 1120</ADDRESS_1>
<ADDRESS_2/>
<CITY>Nijmegen</CITY>
<ZIP>6501 BC</ZIP>
<REGION/>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<PHONE_1>+31 243 297114</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2013-04-29 09:48:14 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="22" MONTH="10" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="28" MONTH="11" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="2" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2013-04-29 09:45:55 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-04-29 09:45:55 +0100" MODIFIED_BY="Anne-Marie Stephani">
<DATE DAY="24" MONTH="4" YEAR="2013"/>
<DESCRIPTION>
<P>New search conducted 28 November 2012; no new studies found.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-04-24 14:27:27 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-04-24 14:27:27 +0100" MODIFIED_BY="Anne-Marie Stephani">
<DATE DAY="15" MONTH="2" YEAR="2010"/>
<DESCRIPTION>
<P>new search conducted; no new studies found</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-02-15 14:02:04 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format with minor editing.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-09 09:34:34 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="5" YEAR="2006"/>
<DESCRIPTION>
<P>2006, Issue 3: Corrected an error in the 'Characteristics of included studies' where the data for 'Participants' were entered in the wrong columns.<BR/>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Department for International Development (DFID)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-04-29 09:48:14 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY>
<TITLE>Not enough evidence on the routine use of surgery in addition to drug treatment for people with tuberculosis of the spine</TITLE>
<SUMMARY_BODY>
<P>Spinal tuberculosis (spinal TB) occurs in about 1% to 2% of people with TB (the most common infectious disease in the world). The disease can have a major impact on people's lives. Nerves can be squeezed causing pain, loss of feeling, and breathing problems. It can cause bone loss and curvature of the spine, which can lead to loss of nerve function and paralysis after some years, even if the TB has been cured. Correcting with surgery at this point can be difficult because of the complexity of the surgery required. It has been suggested that surgery might be undertaken at the time the TB of the spine is diagnosed and drug treatment (chemotherapy) is being used. However, all surgery has potential adverse effects. This review of trials found there were insufficient numbers of participants in the two trials located (331 participants) to be able to say if routine surgery early on was of overall benefit. Further trials are needed and such trials should assess the pain that people suffer and their views of the disease and treatment.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-04-29 09:48:14 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Tuberculosis is generally curable with chemotherapy, but there is controversy in the literature about the need for surgical intervention in the one to two per cent of people with tuberculosis of the spine.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To compare chemotherapy plus surgery with chemotherapy alone for treating people diagnosed with active tuberculosis of the spine.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-04-29 09:48:14 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Infectious Diseases Group Specialized Register (February 2010), CENTRAL (<I>The Cochrane Library</I> 2010, Issue 1), MEDLINE (1966 to February 2010), EMBASE (1974 to February 2010), LILACS (1982 to February 2010), conference proceedings, and reference lists. A search update in November 2012 revealed no new studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomized controlled trials with at least one year follow up that compared chemotherapy plus surgery with chemotherapy alone for treating active tuberculosis of the thoracic and/or lumbar spine.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two authors independently assessed trial eligibility, methodological quality, and extracted data. We analysed data using odds ratio with 95% confidence intervals.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Two randomized controlled trials (331 participants) met the inclusion criteria. They were conducted in the 1970s and 1980s with follow-up reports available after 18 months, three years, and five years; one trial also reported 10 years follow up. Completeness of follow up varied at the different time points, with less than 80% of participants available for analysis at several time points. There was no statistically significant difference for any of the outcome measures: kyphosis angle, neurological deficit (none went on to develop this), bony fusion, absence of spinal tuberculosis, death from any cause, activity level regained, change of allocated treatment, or bone loss. Neither trial reported on pain. Of the 130 participants allocated to chemotherapy only, 12 had a neurological deficit and five needed a decompression operation. One trial suggested that an initial kyphosis angle greater than 30° is likely to deteriorate, especially in children.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>The two included trials had too few participants to be able to say whether routine surgery might help. Although current medication and operative techniques are now far more advanced, these results indicate that routine surgery cannot be recommended unless within the context of a large, well-conducted randomized controlled trial. Clinicians may judge that surgery may be clinically indicated in some groups of patients. Future studies need to address these topics as well as the patient's view of their disease and treatment.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-04-24 14:28:41 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-11-09 13:04:50 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Incidence</HEADING>
<P>Tuberculosis is the most common infectious disease in the world. Every year 10 million new people are infected (<LINK REF="REF-WHO-2005" TYPE="REFERENCE">WHO 2005</LINK>). While tuberculosis commonly infects the lungs, it is located in the spine in one to two per cent of people (<LINK REF="REF-Watts-1996" TYPE="REFERENCE">Watts 1996</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Pathology</HEADING>
<P>Tuberculosis of the spine is potentially serious. The infection can cause pain and destroy the bone making the vertebral bodies collapse, thereby flexing the spine forward (kyphosis) (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Sometimes a nerve root may be compressed causing pain along the root or deficit, but more commonly spinal cord compression may lead to myelopathy (loss of feeling and muscle control) or paraplegia. Even lung function may be compromised (<LINK REF="REF-Smith-1996" TYPE="REFERENCE">Smith 1996</LINK>). If there is a sharp angle in the spine due to bony destruction, loss of neurological function may manifest only after years, even if the tuberculosis has been cured adequately (<LINK REF="REF-Hsu-1988" TYPE="REFERENCE">Hsu 1988</LINK>; <LINK REF="REF-Rajeswari-1997a" TYPE="REFERENCE">Rajeswari 1997a</LINK>; <LINK REF="REF-Luk-1999" TYPE="REFERENCE">Luk 1999</LINK>). This is the result of chronic compression of the spinal cord or a local reactivation. Late paraplegia due to spinal cord compression is a major problem because an operation at this stage is complex and prone to major complications often without subsidence of the neurological deficit (<LINK REF="REF-Moon-1997" TYPE="REFERENCE">Moon 1997</LINK>). If the bone has fully fused in a normal position after the primary illness period, this late consequence is thought not to occur (<LINK REF="REF-Leong-1993" TYPE="REFERENCE">Leong 1993</LINK>).</P>
<P>Most experts believe that a kyphosis over 30° is likely to generate back pain and to deteriorate (<LINK REF="REF-Kaplan-1952" TYPE="REFERENCE">Kaplan 1952</LINK>; <LINK REF="STD-Rajeswari-1997b" TYPE="STUDY">Rajeswari 1997b</LINK>; <LINK REF="REF-Wimmer-1997" TYPE="REFERENCE">Wimmer 1997</LINK>; Parthasarathy 1999 (<I>see</I> <LINK REF="STD-ICMR_x002f_MRC-1989" TYPE="STUDY">ICMR/MRC 1989</LINK>)). Vertebral body bone loss is a measure of destruction of the bone as seen on lateral radiographs. It is expressed as units (U), 1.0 U meaning a complete vertebral body and 0.0 U meaning no bone loss; for example, if two bodies are partially destroyed, one lost 50% of its volume and the other 25%, the bone loss is 0.75 U. It has been claimed to predict the final kyphosis angle (<LINK REF="REF-Rajasekaran-1987" TYPE="REFERENCE">Rajasekaran 1987</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Diagnosis</HEADING>
<P>Diagnosis of spinal tuberculosis in endemic areas is made mainly using radiographs. Active disease is diagnosed when there is loss of the thin cortical outline and rarefaction of the affected vertebral bodies (<LINK REF="STD-MRC-1974a" TYPE="STUDY">MRC 1974a</LINK>). Ideally there is a positive culture from the site of the lesion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Treatment</HEADING>
<P>Tuberculosis in general is curable. The mainstay of treatment is chemotherapy with at least isoniazid, rifampicin, and pyrazinamide. The American Thoracic Society recommends six months of chemotherapy for spinal tuberculosis in adults and 12 months in children because reliable data are lacking on shorter treatment duration (<LINK REF="REF-Bass-1994" TYPE="REFERENCE">Bass 1994</LINK>). The British Thoracic Society recommends six months of treatment irrespective of age (<LINK REF="REF-BTS-1998" TYPE="REFERENCE">BTS 1998</LINK>). In their recent review of the literature, Van Loenhout-Rooyackers and colleagues found that six months of treatment is probably sufficient for everyone (<LINK REF="REF-Van-Loenhout-2002" TYPE="REFERENCE">Van Loenhout 2002</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Goals of treatment</HEADING>
<P>In tuberculosis, treatment is considered to be successful when the person is cured, is no longer infectious, and does not suffer relapse. However, some additional unique problems are encountered in spinal tuberculosis, namely, kyphosis angle and neurological deficit. Treatment in spinal tuberculosis is directed toward controlling or correcting the kyphosis angle thereby restoring the balance of the spine, restoring normal neurology, preventing pain, achieving early bony fusion (healing), preventing local recurrence of spinal tuberculosis, and preventing bone loss. Furthermore, people need to regain their previous activity level to enable them to resume their normal lives, school, jobs, and sports.</P>
<P>Human immunodeficiency virus (HIV) increases the risk of reactivation of a latent focus and progression of the disease to a more atypical and severe course. Studies directed specifically at spinal tuberculosis and HIV conclude that good clinical outcomes can be expected irrespective of the HIV status and the availability of antiretroviral therapy (<LINK REF="REF-Leibert-1996" TYPE="REFERENCE">Leibert 1996</LINK>; <LINK REF="REF-Govender-2000" TYPE="REFERENCE">Govender 2000</LINK>). Another report mentions that people with HIV are not a homogeneous group, and that results &#8722; especially complications like wound infections &#8722; worsen during the end stage of the disease (<LINK REF="REF-Jellis-1996" TYPE="REFERENCE">Jellis 1996</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Role of surgery</HEADING>
<P>There is controversy in the literature about the necessity of additional surgical intervention to spinal tuberculosis treatments. This difference of opinion goes back to 1960 when Hodgson and Stock advocated surgical treatment (<LINK REF="REF-Hodgson-1960" TYPE="REFERENCE">Hodgson 1960</LINK>), and Konstam and colleagues advocated conservative treatment (<LINK REF="REF-Konstam-1958" TYPE="REFERENCE">Konstam 1958</LINK>; <LINK REF="REF-Konstam-1962" TYPE="REFERENCE">Konstam 1962</LINK>). Conservative treatment consists of only medication and sometimes additional non-operative measures (physical therapy, orthosis, and bed rest). Surgery can basically be divided into two procedures. The first is a debridement. This is a procedure that comprises surgical removal of the infected material. No attempt is made at stabilizing the spine. The second form, which is more extensive, is a debridement with stabilization of the spine (spinal reconstruction). The reconstruction has always been performed with bone grafts. Today, countries with sufficient resources perform stabilization using artificial materials like steel, carbon fibre, or titanium (instrumentation).</P>
<P>Although randomized controlled trials investigating indications are lacking, many authors consider the following indications for surgical intervention: (1) neurological deficits (with an acute or non-acute onset) caused by compression of the spinal cord; (2) spinal instability caused by destruction or collapse of the vertebrae, destruction of two or more vertebrae, or kyphosis of more than 30°; (3) no response to chemotherapeutic treatment; (4) non-diagnostic biopsy; and (5) large paraspinal abscesses (<LINK REF="REF-Vidyasagar-1994" TYPE="REFERENCE">Vidyasagar 1994</LINK>; <LINK REF="REF-Chen-1995" TYPE="REFERENCE">Chen 1995</LINK>; <LINK REF="REF-Nussbaum-1995" TYPE="REFERENCE">Nussbaum 1995</LINK>; <LINK REF="REF-Rezai-1995" TYPE="REFERENCE">Rezai 1995</LINK>; <LINK REF="REF-Boachie_x002d_Adjei-1996" TYPE="REFERENCE">Boachie-Adjei 1996</LINK>; <LINK REF="REF-Watts-1996" TYPE="REFERENCE">Watts 1996</LINK>; <LINK REF="REF-Moon-1997" TYPE="REFERENCE">Moon 1997</LINK>). Some authors even advocate surgery in mild cases of spinal tuberculosis (<LINK REF="REF-Leong-1993" TYPE="REFERENCE">Leong 1993</LINK>; <LINK REF="REF-Luk-1999" TYPE="REFERENCE">Luk 1999</LINK>; <LINK REF="REF-Turgut-2001" TYPE="REFERENCE">Turgut 2001</LINK>).</P>
<P>Potential benefits of surgery are less kyphosis, immediate relief of compressed neural tissue, quicker relief of pain, a higher percentage of bony fusion, quicker bony fusion, less relapse, earlier return to previous activities, and less bone loss. It may also prevent late neurological problems due to kyphosis of the spine if fusion has not occurred (<LINK REF="REF-Hsu-1988" TYPE="REFERENCE">Hsu 1988</LINK>; <LINK REF="REF-Leong-1993" TYPE="REFERENCE">Leong 1993</LINK>).</P>
<P>Surgery requires expertise, good anaesthesia, and excellent peri-operative care. It also requires hospitalization, and is expensive and potentially dangerous. Complications can occur during the operation or postoperatively. Complications of spinal surgery can be divided into several groups: reconstruction-related, vascular, neurological, visceral, and wound-related. Reconstruction failures can be breakage of the graft, screws and rods, loss of correction, and failure of fusion (<LINK REF="REF-Jutte-2002" TYPE="REFERENCE">Jutte 2002</LINK>). Vascular problems during surgery can be massive bleeding, haematoma formation, and thromboembolism. Neurological damage of surgery can be nerve root lesion, dura tears, spinal cord infarction, and plexus lesions. Visceral damage, especially ureteric lesions, can occur. Wound infections happen in 1% to 6% of spinal surgeries (<LINK REF="REF-Fardon-2002" TYPE="REFERENCE">Fardon 2002</LINK>). Considering the potential complication rate, surgery should only be performed if there is a clear benefit.</P>
</SUBSECTION>
</BACKGROUND>
<OBJECTIVES>
<P>To compare chemotherapy plus surgery with chemotherapy alone for treating people diagnosed with active tuberculosis of the spine.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-04-24 14:28:41 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-11-09 13:04:50 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>Randomized controlled trials with at least one year follow up after the start of treatment.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-11-09 13:04:50 +0000" MODIFIED_BY="[Empty name]">
<P>People diagnosed with active tuberculosis of the thoracic and/or lumbar spine, including the upper sacral vertebra S1 (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<P>Active disease is diagnosed on the radiographs; there is loss of the thin cortical outline and rarefaction of the affected vertebral bodies (<LINK REF="STD-MRC-1973a" TYPE="STUDY">MRC 1973a</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-11-09 09:35:24 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Intervention</HEADING>
<P>Chemotherapy plus surgery.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Control</HEADING>
<P>Chemotherapy.</P>
<P>
<I>Both the intervention and control group must have received comparable adequate chemotherapy regimen of at least six months. Adequate refers to the guidelines commonly used when the trial took place.</I>
</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-11-05 13:23:18 +0000" MODIFIED_BY="[Empty name]">
<P>We assessed all outcome parameters reported at any follow-up time.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary</HEADING>
<UL>
<LI>Kyphosis angle.</LI>
<LI>Neurological deficit.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary</HEADING>
<UL>
<LI>Pain.</LI>
<LI>Bony fusion, defined as the healing of adjacent affected vertebral bodies. There is continuity of trabeculae (bone bars) between the vertebral bodies and/or stout bony bridges, usually best seen in the anteroposterior radiograph, projecting up to 2 cm wide of the vertebral bodies and showing trabecular continuity even though the vertebrae are still separated by a small space, often no more than a hairline.</LI>
<LI>Absence of spinal tuberculosis.</LI>
<LI>Deaths from any cause.</LI>
<LI>Regained activity level, defined as the number of participants that regained their previous activity level, which is the ability of people to resume their normal lives, do their previous jobs, sports, etc.</LI>
<LI>Bone loss, defined as a measure of destruction of the bone as seen on lateral radiographs. It is expressed as units (U), 1.0 U being loss of a complete vertebral body and 0.0 U being no bone loss; for example, if two bodies are partially destroyed, one lost 50% of its volume and the other 25%, the bone loss is 0.75 U.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<P>Events related or probably related to the treatment having a negative effect on the well-being of the participants other than death (reported separately); this includes surgical complications, failure of reconstruction, paraplegia from the operation, and adverse effects of medication.</P>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-04-24 14:28:41 +0100" MODIFIED_BY="[Empty name]">
<P>We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress).</P>
<SUBSECTION>
<HEADING LEVEL="3">Databases</HEADING>
<P>We searched the following databases using the search terms and strategy described in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. Cochrane Infectious Diseases Group Specialized Register (February 2010); Cochrane Central Register of Controlled Trials (CENTRAL), published in <I>The Cochrane Library </I>(2010, Issue 1); MEDLINE (1966 to February 2010); EMBASE (1974 to February 2010); LILACS (1982 to February 2010). A search update was conducted on 28 November 2012.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Reference lists</HEADING>
<P>We also checked the reference lists of all studies identified by the above methods.</P>
</SUBSECTION>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-11-09 13:04:50 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2008-11-09 09:35:48 +0000" MODIFIED_BY="[Empty name]">
<P>We scanned the results of the literature search for potentially relevant trials and retrieved their full articles. We independently assessed the potentially relevant trials for inclusion in the review using an eligibility form based on the inclusion criteria. We ensured each trial was included only once and resolved disagreements through discussion. The excluded studies are listed together with the reason for excluding them in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>'.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-11-09 13:04:50 +0000" MODIFIED_BY="[Empty name]">
<P>The first author extracted the data using a data extraction form and entered the data into <LINK REF="REF-Review-Manager-5" TYPE="REFERENCE">Review Manager 5</LINK>. The second author cross checked the data with the original paper. We also extracted the number of participants allocated to surgery who were not operated on, and those allocated to chemotherapy alone who received surgery. We resolved disagreements by referring to the original paper.</P>
<P>Data on neurology, pain, bony fusion, absence of spinal tuberculosis, death from any cause, activity level, and change of allocated treatment were handled as dichotomous data. Data on angle of kyphosis can be handled as continuous or dichotomous. Continuous was preferred, but the required data on standard deviation were not provided. We handled the data as dichotomous data in two ways: (a) a final kyphosis angle being &#8804; 30° or &gt; 30°; and (b) a progression &#8804; 10° or &gt; 10°.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-11-09 13:04:50 +0000" MODIFIED_BY="[Empty name]">
<P>We independently assessed the methods used to generate the allocation sequence and conceal allocation as adequate, inadequate, or unclear according to <LINK REF="REF-J_x00fc_ni-2001" TYPE="REFERENCE">Jüni 2001</LINK>. We also assessed the inclusion of all randomized participants in the final analysis and considered at least 80% completeness of follow up at each time point to be adequate. Blinding of the treating physicians was not possible at the time of treatment or at follow up. Blinding of the assessor of the radiographs of both trials was limited to pre-treatment investigations. At follow up, no information of the treatment given was provided; signs can frequently be seen on radiographs after an operation, especially after a reconstruction with a bone graft. We resolved any disagreements through discussion.</P>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-11-09 13:04:50 +0000" MODIFIED_BY="[Empty name]">
<P>We analysed the data using <LINK REF="REF-Review-Manager-5" TYPE="REFERENCE">Review Manager 5</LINK>. We used odds ratio (OR) to assess all dichotomous outcome measures. We used the fixed-effect model and presented the data with 95% confidence intervals (CI).</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-11-09 13:04:50 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-11-09 13:04:50 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Search results</HEADING>
<P>The search strategy revealed 25 potentially relevant papers; their reference lists revealed another three. We studied the full-text versions of all 28 papers. We excluded 21 papers (<I>see </I>'<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>') and included seven publications reporting on two randomized controlled trials involving 331 participants (<I>see </I>'<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>').</P>
<P>The British Medical Research Council Working Party on Tuberculosis of the Spine (MRC) co-ordinated both randomized controlled trials, one in co-operation with the Indian Council of Medical Research (ICMR). The MRC performed a series of randomized controlled trials investigating the varying ways of treatment of tuberculosis of the spine in several centres. This review includes two of these trials: one from Bulawayo, Rhodesia (now Zimbabwe) (<LINK REF="STD-MRC-1974a" TYPE="STUDY">MRC 1974a</LINK>); and the other from Madras, India (<LINK REF="STD-ICMR_x002f_MRC-1989" TYPE="STUDY">ICMR/MRC 1989</LINK>).</P>
<P>The different publications reported on the trials after 18 months, three years, and five years (<LINK REF="STD-MRC-1974a" TYPE="STUDY">MRC 1974a</LINK>; <LINK REF="STD-ICMR_x002f_MRC-1989" TYPE="STUDY">ICMR/MRC 1989</LINK>); <LINK REF="STD-ICMR_x002f_MRC-1989" TYPE="STUDY">ICMR/MRC 1989</LINK> also reported 10 years follow up. The results at five years for <LINK REF="STD-ICMR_x002f_MRC-1989" TYPE="STUDY">ICMR/MRC 1989</LINK> were described in three different papers. We used an article published by the MRC in 1999 to assess the five year follow up of <LINK REF="STD-ICMR_x002f_MRC-1989" TYPE="STUDY">ICMR/MRC 1989</LINK> as it is the official report of the trial and provides the most detailed information of all three.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Participants</HEADING>
<P>We have detailed the inclusion and exclusion criteria in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' and summarized the characteristics of the 331 enrolled and randomized participants in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>. Trials reported on the number of participants evaluable at the various times of follow up (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> and <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). Both trials included children (less than 15 years old) and adults, men and women. The location of the spinal lesion was thoracic (T1 to T10), thoracolumbar (T11 to L2), and/or lumbosacral (L2 to S1) (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). A few participants had neurological deficit on entry but all were able to walk.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Interventions</HEADING>
<P>
<LINK REF="STD-MRC-1974a" TYPE="STUDY">MRC 1974a</LINK> randomized 130 people to chemotherapy plus surgical debridement (no reconstruction) or chemotherapy alone. All participants received p-amino salicylic acid (PAS) and isoniazid for 18 months. Half of them were randomized to receive streptomycin as extra in the first three months. We were unable to determine exactly which individual participants received streptomycin, but for the purpose of this review we did not consider this a reason for exclusion. Streptomycin is not a potent drug in the treatment of tuberculosis and is no longer part of the recommended treatment regimen (<LINK REF="REF-Bass-1994" TYPE="REFERENCE">Bass 1994</LINK>; <LINK REF="REF-BTS-1998" TYPE="REFERENCE">BTS 1998</LINK>).</P>
<P>
<LINK REF="STD-ICMR_x002f_MRC-1989" TYPE="STUDY">ICMR/MRC 1989</LINK> randomized 201 participants to chemotherapy plus surgery (debridement and reconstruction with bone graft) or to chemotherapy alone. The chemotherapy for all participants was a six-month regimen of isoniazid and rifampicin. The trial also included a third arm, which we had to exclude because these participants received a different chemotherapy regimen consisting of nine months treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcomes</HEADING>
<P>The trials reported on all the prespecified outcome measures except pain.</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-11-09 13:04:50 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>See '</I>
<LINK TAG="QUALITY_ASSESSMENT" TYPE="SECTION">Assessment of risk of bias in included studies</LINK>
<I>' for details and a summary of the quality assessment in </I>
<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>.</P>
<P>The methods used to generate the allocation sequence were unclear in both trials, but the concealment of allocation was adequate. Completeness of follow up in the <LINK REF="STD-MRC-1974a" TYPE="STUDY">MRC 1974a</LINK> trial was inadequate after three years (72%) and five years (62%). In the <LINK REF="STD-ICMR_x002f_MRC-1989" TYPE="STUDY">ICMR/MRC 1989</LINK> trial, it was adequate at three years (83%) and five years (82%), but inadequate at 10 years (78%).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-11-09 13:04:50 +0000" MODIFIED_BY="[Empty name]">
<P>Analysis in the two trials appeared to be by intention to treat. In the chemotherapy group across the two trials, 12 participants had neurological complications at entry to the trial: five of these required surgery. Details on reasons behind the change of allocated treatment are given in <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>. In the chemotherapy plus surgery group across the two trials, there was a problem with exposure of the bone during operation in two participants and the procedure was abandoned: both were treated with chemotherapy only. We looked for a difference in the numbers of participants where their actual treatment group was different to what they were originally randomized to and detected no difference (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Kyphosis angle</HEADING>
<P>Both trials reported on kyphosis angle. They used two methods to report change in the angle.</P>
<SUBSECTION>
<HEADING LEVEL="4">Mean increase of kyphosis angle (progression of kyphosis angle at follow up)</HEADING>
<P>Both trials reported that the mean degree of kyphosis angle was within the same range at 18 months, three years, five years, and 10 years (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>), but we were unable to assess statistical significance because standard deviations were not provided.</P>
<P>In <LINK REF="STD-ICMR_x002f_MRC-1989" TYPE="STUDY">ICMR/MRC 1989</LINK> at 10 years follow up, a kyphosis of greater than 30° at the start of treatment deteriorated (increased) with a mean of 10° to 30°. The investigators describe a subgroup effect for age on kyphosis angle for the chemotherapy group: 17 participants younger than 15 years with an initial angle greater than 30° had a mean deterioration of 30° compared with the same treatment in 13 participants older than 15 years with angles greater than 30° who deteriorated with a mean of 10° (P = 0.001).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Kyphosis angle: &gt; 10° deterioration</HEADING>
<P>
<LINK REF="STD-MRC-1974a" TYPE="STUDY">MRC 1974a</LINK> measured this at five years (65 participants) for lesions in the thoracic, thoracolumbar, and lumbosacral areas (T1 to S1), and <LINK REF="STD-ICMR_x002f_MRC-1989" TYPE="STUDY">ICMR/MRC 1989</LINK> measured this at three years (78 participants) and five years (79 participants) for lesions in the thoracic and thoracolumbar areas (T1 to L2). There was no statistically significant difference between groups at three years (78 participants, 1 trial) or five years (144 participants, 2 trials); <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Neurological deficit</HEADING>
<P>Both sets of trials reported on the neurological status of the participants. No participants without neurological deficit on entry developed neurological deficit. Neurological deficit was present at entry in 23 participants and there was no statistically significant difference at 18 months (23 participants, 2 trials), three years (23 participants, 2 trials), five years (20 participants, 2 trials), and 10 years (10 participants, 1 trial); <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Pain</HEADING>
<P>Neither trial reported on pain.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Bony fusion</HEADING>
<P>There was no statistically significant difference between chemotherapy plus surgery and chemotherapy alone on the presence of bony fusion at 18 months (256 participants, 2 trials), three years (247 participants, 2 trials), five years (236 participants, 2 trials), or 10 years (156 participants, 1 trial); <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Absence of spinal tuberculosis</HEADING>
<P>There was no statistically significant difference between the intervention and control at 18 months (261 participants, 2 trials), three years (262 participants, 2 trials), five years (244 participants, 2 trials), and 10 years (156 participants, 1 trial);<I> </I>
<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Deaths from any cause</HEADING>
<P>Both sets of trials reported on deaths from any cause (details provided in <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>). There was no statistically significant difference between the groups at 18 months (262 participants, 2 trials) or three years (262 participants, 2 trials); <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>. Follow up at five or 10 years was impossible to assess because details on which patient died in which group were not provided.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Regained activity level</HEADING>
<P>Both sets of trials reported on activity level, but neither provided data on the participants' activity levels when they entered the trials. Around 90% of participants in both groups had reached their previous level of activity at 18 months follow up. One of the prerequisites for regaining activity level is normal neurology. There were no statistically significant differences between the groups at 18 months (262 participants, 2 trials), three years (262 participants, 2 trials), five years (244 participants, 2 trials), or 10 years (156 participants, 1 trial); <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Bone loss</HEADING>
<P>The trials used two methods of reporting data on bone loss.</P>
<SUBSECTION>
<HEADING LEVEL="4">Mean change of bone loss (mean difference between loss at entry and at follow up)</HEADING>
<P>Neither trial report included standard deviations, which meant that we were unable to assess the statistical significance of the data on the mean bone losses. The major bone loss (vertebral destruction) was present at the time of diagnosis; only limited further destruction occurred during treatment and the subsequent follow-up period (<I>see</I> <LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Large change in bone loss</HEADING>
<P>An unwanted result is considered when the amount of bone loss has deteriorated greater than 0.25 U. <LINK REF="STD-MRC-1974a" TYPE="STUDY">MRC 1974a</LINK> reported on this at five years (58 participants), and <LINK REF="STD-ICMR_x002f_MRC-1989" TYPE="STUDY">ICMR/MRC 1989</LINK> reported data at three years (161 participants) and five years (150 participants). There was no statistically significant difference at three years (161 participants, 1 trial) or five years (220 participants, 2 trials); <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events</HEADING>
<P>Adverse events were defined as events related or probably related to the treatment having a negative effect on the well-being of the participants other than death (reported separately). Adverse events were not specifically reported by the trial authors, so we analysed the text to identify them (<LINK REF="APP-08" TYPE="APPENDIX">Appendix 8</LINK>). One participant was operated on the wrong localization, there were seven graft failures (breakage and displacement), and 28 cases of hepatitis, a side effect of the chemotherapy.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-11-09 13:04:50 +0000" MODIFIED_BY="[Empty name]">
<P>The objective of this systematic review was to compare chemotherapy plus surgery with chemotherapy alone for treating people diagnosed with active tuberculosis of the thoracic and/or lumbar spine. No statistically significant benefit of routine surgery was found. Most participants received the treatment of the group to which they were allocated. Reasons for changing treatment were mainly neurological: five of 12 participants from the chemotherapy group had surgery because of persisting or deteriorating neurological deficit. Participants with neurological deficit form an interesting subgroup for further studies.</P>
<SUBSECTION>
<HEADING LEVEL="2">Effects on the spine</HEADING>
<P>The review did not demonstrate an effect of surgery on the kyphosis angle. The incidence of progressive kyphosis was high for all participants, as was the kyphosis angle at the start of either treatment. Many spine surgeons nowadays consider a kyphosis greater than 30° to be unacceptably high and an indication for operative correction in the first place (<LINK REF="REF-Vidyasagar-1994" TYPE="REFERENCE">Vidyasagar 1994</LINK>; <LINK REF="REF-Chen-1995" TYPE="REFERENCE">Chen 1995</LINK>; <LINK REF="REF-Nussbaum-1995" TYPE="REFERENCE">Nussbaum 1995</LINK>; <LINK REF="REF-Rezai-1995" TYPE="REFERENCE">Rezai 1995</LINK>; <LINK REF="REF-Boachie_x002d_Adjei-1996" TYPE="REFERENCE">Boachie-Adjei 1996</LINK>; <LINK REF="REF-Watts-1996" TYPE="REFERENCE">Watts 1996</LINK>; <LINK REF="REF-Moon-1997" TYPE="REFERENCE">Moon 1997</LINK>). Nor did the review show a difference with respect to bony fusion, often considered the best evidence of healing (<LINK REF="STD-MRC-1974a" TYPE="STUDY">MRC 1974a</LINK>). Further deterioration of the kyphosis angle is unlikely after fusion. There was no statistically significant difference between the two intervention groups on the presence of bony fusion at any reported follow up. Data on the speed of bony fusion were not provided in either trial, so differences during early phases of treatment could not be assessed. Over time, bony fusion is obtained in a high percentage of participants regardless of the way of treatment. Similarly, bone loss was not influenced by treatment group. The amount of bone is considered important for the stability of the spine. People with a total bone loss of more than three U were excluded, and the role of surgery in these more severe cases could not be assessed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Neurological deficit and mobility</HEADING>
<P>A small number of participants had a neurological deficit at entry, and there were no statistically significant differences between the interventions in the improvement of this deficit. Deterioration of neurological deficit or persisting deficit with spinal cord compression can be an indication for surgery (<LINK REF="REF-Martini-1976" TYPE="REFERENCE">Martini 1976</LINK>; <LINK REF="REF-Leong-1993" TYPE="REFERENCE">Leong 1993</LINK>; <LINK REF="REF-Watts-1996" TYPE="REFERENCE">Watts 1996</LINK>; <LINK REF="REF-Moon-1997" TYPE="REFERENCE">Moon 1997</LINK>). There was a subgroup of 12 participants from the chemotherapy only group (130) with neurological deficit on entry; five of these 12 needed an operation to decompress the spinal cord.</P>
<P>Two studies reporting on non-surgical treatment of spinal tuberculosis conclude that it is successful in the majority of cases, even in the presence of neurological deficit (<LINK REF="REF-Pattison-1986" TYPE="REFERENCE">Pattison 1986</LINK>; <LINK REF="REF-Nene-2005" TYPE="REFERENCE">Nene 2005</LINK>). However, the participants were not randomized, one of the studies was retrospective (<LINK REF="REF-Nene-2005" TYPE="REFERENCE">Nene 2005</LINK>), and the follow up was 25% at five years for the other report (<LINK REF="REF-Pattison-1986" TYPE="REFERENCE">Pattison 1986</LINK>).</P>
<P>Some authors advocate the so-called 'middle path regimen' in which only patients with neurological deficit have operations (<LINK REF="REF-Tuli-1975" TYPE="REFERENCE">Tuli 1975</LINK>; <LINK REF="STD-Jain-2004" TYPE="STUDY">Jain 2004</LINK>). They report good results, but there are no trials comparing this regimen to purely non-surgical treatment or routine surgical treatment. None of the participants included in the included trials were paralysed severely enough to prevent them from walking across a room. Therefore the role of surgery in these more severe cases could not be assessed.</P>
<P>Almost all participants reached their previous activity levels at first follow up, regardless of treatment. However, data on activity level on entry of the study were not provided, so the actual improvement could not be assessed. Furthermore, there may have been differences in the speed of recovery. Regrettably neither trial assessed this.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Deaths and adverse events</HEADING>
<P>There was no statistically significant difference in the number of deaths from any cause at 18 months or three years follow up. Because the trials did not provide details, we were unable to assess the mortality at five or 10 years. In <LINK REF="STD-ICMR_x002f_MRC-1989" TYPE="STUDY">ICMR/MRC 1989</LINK>, four participants died as a consequence of surgical procedures. The procedure was introduced to the orthopaedic centre for this particular trial. Because of these deaths, the investigators concluded that there are problems in introducing a new major surgical procedure, even in an orthopaedic centre, and suggest that in the light of the excellent results achieved by chemotherapy alone that this procedure need not and should not be introduced (<LINK REF="STD-ICMR_x002f_MRC-1989" TYPE="STUDY">ICMR/MRC 1989</LINK>). The operations with their high mortality rate (4/85) were performed between 1975 and 1978. Perioperative care has improved since, and no deaths have been reported from more recent series of operations (<LINK REF="REF-G_x00fc_ven-1994" TYPE="REFERENCE">Güven 1994</LINK>; <LINK REF="REF-Rezai-1995" TYPE="REFERENCE">Rezai 1995</LINK>; <LINK REF="REF-Lee-1999" TYPE="REFERENCE">Lee 1999</LINK>; <LINK REF="REF-Turgut-2001" TYPE="REFERENCE">Turgut 2001</LINK>; <LINK REF="REF-Sundararaj-2003" TYPE="REFERENCE">Sundararaj 2003</LINK>).</P>
<P>Most adverse events were related to surgery. In <LINK REF="STD-ICMR_x002f_MRC-1989" TYPE="STUDY">ICMR/MRC 1989</LINK>, four people died due to complications related to surgery, some of these are preventable with modern day knowledge. There were several problems related to the bone graft. The same trial reported that three or more disc spaces had to be spanned in seven participants with a kyphosis greater than 30°. All seven bone grafts failed (breakage or displacement) and the deformity progressed. Modern spinal instrumentation might prevent this failure.</P>
<P>There were no participants reported with cardio-respiratory failure related to the deformity. In neither series there were participants with late paraplegia in spite of some severe deformities. Follow up of 10 years might not be sufficient for this late paraplegia; it may only manifest itself after more than 15 years (<LINK REF="REF-Seddon-1935" TYPE="REFERENCE">Seddon 1935</LINK>; <LINK REF="REF-Hsu-1988" TYPE="REFERENCE">Hsu 1988</LINK>; <LINK REF="REF-Leong-1993" TYPE="REFERENCE">Leong 1993</LINK>; <LINK REF="REF-Luk-1999" TYPE="REFERENCE">Luk 1999</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Limitations of the review</HEADING>
<P>Follow up was inadequate for <LINK REF="STD-MRC-1974a" TYPE="STUDY">MRC 1974a</LINK> at any time point and for 10 years follow up of <LINK REF="STD-ICMR_x002f_MRC-1989" TYPE="STUDY">ICMR/MRC 1989</LINK>. In both sets of trials different techniques of surgery were used: debridement surgery (<LINK REF="STD-MRC-1974a" TYPE="STUDY">MRC 1974a</LINK>) and debridement plus reconstruction with bone graft (<LINK REF="STD-ICMR_x002f_MRC-1989" TYPE="STUDY">ICMR/MRC 1989</LINK>). As shown in the meta-analyses, there were no statistically significant differences between these techniques. Both sets of trials were performed many years ago, between 1964 and 1969 for <LINK REF="STD-MRC-1974a" TYPE="STUDY">MRC 1974a</LINK> and between 1975 and 1978 for <LINK REF="STD-ICMR_x002f_MRC-1989" TYPE="STUDY">ICMR/MRC 1989</LINK>. In recent years, new medications and better operative techniques have been developed.</P>
<P>The introduction of pyrazinamide in 1978 dropped the relapse rates for pulmonary tuberculosis from 7.8% and 20.3% to 1.4% and 3.4% after two and five years follow up, respectively (<LINK REF="REF-MRC-1987" TYPE="REFERENCE">MRC 1987</LINK>). Randomized controlled trials are needed to assess this newer medication in spinal tuberculosis.</P>
<P>Better techniques for correcting deformities of the spine like kyphosis and scoliosis are continually being developed. These techniques using metal or titanium screws, plates, and rods (instrumentation) have reported to be good at maintaining this correction (<LINK REF="REF-G_x00fc_ven-1994" TYPE="REFERENCE">Güven 1994</LINK>; <LINK REF="REF-Moon-1995" TYPE="REFERENCE">Moon 1995</LINK>; <LINK REF="STD-Rajasekaran-1998" TYPE="STUDY">Rajasekaran 1998</LINK>; <LINK REF="REF-Lee-1999" TYPE="REFERENCE">Lee 1999</LINK>; <LINK REF="REF-_x00d6_zdemir-2003" TYPE="REFERENCE">Özdemir 2003</LINK>; <LINK REF="REF-Sundararaj-2003" TYPE="REFERENCE">Sundararaj 2003</LINK>). However, no randomized controlled trials have been performed comparing chemotherapy alone with chemotherapy plus surgical instrumentation, and they are unlikely to be conducted because the main debate in spinal surgery is now whether the instrumentation should be anterior, posterior, or both (<LINK REF="REF-G_x00fc_ven-1994" TYPE="REFERENCE">Güven 1994</LINK>; <LINK REF="REF-Moon-1995" TYPE="REFERENCE">Moon 1995</LINK>; <LINK REF="REF-Moon-1997" TYPE="REFERENCE">Moon 1997</LINK>; <LINK REF="STD-Rajasekaran-1998" TYPE="STUDY">Rajasekaran 1998</LINK>; <LINK REF="REF-_x00d6_zdemir-2003" TYPE="REFERENCE">Özdemir 2003</LINK>; <LINK REF="REF-Sundararaj-2003" TYPE="REFERENCE">Sundararaj 2003</LINK>).<BR/>
<BR/>Another limitation of the review is that there were no data on how the patients found their treatment. It would be helpful if future studies also address this point.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Two trials evaluated routine surgery in spinal tuberculosis, but data are insufficient to be clear whether this policy is better than chemotherapy alone (with surgery used when clinically indicated). These trials were performed some years ago, and current medication and operative techniques are far more advanced. However, these results indicate that routine surgery cannot be recommended unless within the context of a large, well-conducted randomized controlled trial. </P>
<P>Clinicians may judge that surgery may be indicated in subgroups of patients &#8722; with an initial kyphosis angle greater than 30° (especially in children) or progressive or persistent neurological deficit with spinal cord compression despite chemotherapy &#8722; but there are no randomized comparisons to support this.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Future trials need to assess routine surgery and also address subgroups of patients with spinal tuberculosis to establish the role of surgery for specific indications. These trials need to be large enough to assess outcomes properly. They need to assess pain and the patient's view of their disease and treatment.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>This document is an output from a project funded by the UK Department for International Development (DFID) for the benefit of developing countries. The views expressed are not necessarily those of DFID.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Paul Jutte took the lead in preparing the review and is the guarantor. Joke van Loenhout-Rooyackers helped design the study, write the background, determine the outcome measures, and also cross checked all data.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2008-11-09 09:33:59 +0000" MODIFIED_BY="[Empty name]">
<P>2006, Issue 1 (first version of review): We added a new outcome, bone loss, because both trials included data on this. In our protocol, we had stated that we would consider outcomes reported between 12 and 24 months because we did not expect to find trials that followed participants for a longer period. Both included trials follow the participants for much longer, so we decided to report on all outcomes reported. We modified one of the subgroup group analyses so that the cut-off age for children became 15 years old instead of 18 years old (as stated in the protocol) because 15 years old is generally when growth stops and both trials used this age. We were however unable to use some methods described in the protocol because there were too few included trials.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-09 09:48:11 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-11-05 16:27:55 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-11-05 14:48:13 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-ICMR_x002f_MRC-1989" MODIFIED="2008-11-05 14:48:13 +0000" MODIFIED_BY="[Empty name]" NAME="ICMR/MRC 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Balasubramanian R, Sivasubramanian S, Parthasarathy R, Santha T, Somasundaram PR, Shanmugasundaram TK, et al</AU>
<TI>Prevalence, incidence and resolution of abscesses and sinuses in patients with tuberculosis of the spine: 5-year results of patients treated with short-course chemotherapy with or without surgery in Madras</TI>
<SO>Indian Journal of Tuberculosis</SO>
<YR>1994</YR>
<VL>41</VL>
<NO>3</NO>
<PG>151-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Indian Council of Medical Research/British Medical Research Council Working Party</AU>
<TI>A controlled trial of short-course regimens of chemotherapy in patients receiving ambulatory treatment or undergoing radical surgery for tuberculosis of the spine</TI>
<SO>Indian Journal of Tuberculosis</SO>
<YR>1989</YR>
<VL>36 Suppl</VL>
<PG>1-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-11-05 14:48:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Medical Research Council Working Party on Tuberculosis of the Spine</AU>
<TI>Five-year assessment of controlled trials of short-course chemotherapy regimens of 6, 9 or 18 months' duration for spinal tuberculosis in patients ambulatory from the start or undergoing radical surgery. Fourteenth report of the Medical Research Council Working Party on Tuberculosis of the Spine</TI>
<SO>International Orthopaedics</SO>
<YR>1999</YR>
<VL>23</VL>
<NO>2</NO>
<PG>73-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parthasarathy R, Sriram K, Santha T, Prabhakar R, Somasundaram PR, Sivasubramanian S</AU>
<TI>Short-course chemotherapy for tuberculosis of the spine. A comparison between ambulant treatment and radical surgery--ten-year report</TI>
<SO>Journal of Bone and Joint Surgery</SO>
<YR>1999</YR>
<VL>81-B</VL>
<NO>3</NO>
<PG>464-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reetha AM, Sivasubramanian S, Parthasarathy R, Somasundaram PR, Prabhakar R</AU>
<TI>Five-year findings of a comparison of ambulatory short-course chemotherapy with radical surgery plus chemotherapy for tuberculosis of the spine in Madras</TI>
<SO>Indian Journal of Orthopaedics</SO>
<YR>1994</YR>
<VL>28</VL>
<NO>1</NO>
<PG>7-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MRC-1974a" MODIFIED="2008-11-05 14:46:07 +0000" MODIFIED_BY="[Empty name]" NAME="MRC 1974a" YEAR="1974">
<REFERENCE MODIFIED="2008-11-05 14:46:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>A controlled trial of debridement and ambulatory treatment in the management of tuberculosis of the spine in patients on standard chemotherapy. A study in Bulawayo, Rhodesia</TI>
<SO>Journal of Tropical Medicine and Hygeine</SO>
<YR>1974</YR>
<VL>77</VL>
<NO>4</NO>
<PG>72-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Medical Research Council Working Party on Tuberculosis of the Spine</AU>
<TI>Five-year assessments of controlled trials of ambulatory treatment, debridement and anterior spinal fusion in the management of tuberculosis of the spine. Studies in Bulawayo (Rhodesia) and in Hong Kong. Sixth report of the Medical Research Council Working Party on Tuberculosis of the Spine</TI>
<SO>Journal of Bone and Joint Surgery</SO>
<YR>1978</YR>
<VL>60-B</VL>
<NO>2</NO>
<PG>163-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-11-05 16:27:55 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Jain-2004" NAME="Jain 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jain AK, Aggarwal PK, Arora A, Singh S</AU>
<TI>Behaviour of the kyphotic angle in spinal tuberculosis</TI>
<SO>International Orhtopaedics</SO>
<YR>2004</YR>
<VL>28</VL>
<NO>2</NO>
<PG>110-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loembe-1994" NAME="Loembe 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loembe PM</AU>
<TI>Medico-surgical treatment of Pott's disease. Our attitude in Gabon</TI>
<TO>Traitement medico-chirurgical du mal de Pott de l'adulte. Notre attitude a Gabon</TO>
<SO>Le Journal Canadien des Sciences Neurologiques</SO>
<YR>1994</YR>
<VL>21</VL>
<NO>4</NO>
<PG>339-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MRC-1973a" MODIFIED="2008-11-05 14:52:41 +0000" MODIFIED_BY="[Empty name]" NAME="MRC 1973a" YEAR="1973">
<REFERENCE MODIFIED="2008-11-05 14:52:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>No authors listed</AU>
<TI>A controlled trial of ambulant out-patient treatment and in-patient rest in bed in the management of tuberculosis of the spine in young Korean patients on standard chemotherapy a study in Masan, Korea. First report of the Medical Research Council Working Party on Tuberculosis of the Spine</TI>
<SO>Journal of Bone and Joint Surgery</SO>
<YR>1973</YR>
<VL>55-B</VL>
<NO>4</NO>
<PG>678-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MRC-1973b" MODIFIED="2008-11-05 16:27:55 +0000" MODIFIED_BY="[Empty name]" NAME="MRC 1973b" YEAR="1973">
<REFERENCE MODIFIED="2008-11-05 16:27:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Medical Research Council Working Party on Tuberculosis of the Spine</AU>
<TI>A controlled trial of plaster-of-paris jackets in the management of ambulant outpatient treatment of tuberculosis of the spine in children on standard chemotherapy. A study in Pusan, Korea. Second report of the Medical Research Council Working Party on Tuberculosis of the Spine</TI>
<SO>Tubercle</SO>
<YR>1973</YR>
<VL>54</VL>
<NO>4</NO>
<PG>261-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MRC-1974b" NAME="MRC 1974b" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<TI>A controlled trial of anterior spinal fusion and debridement in the surgical management of tuberculosis of the spine in patients on standard chemotherapy: a study in Hong Kong</TI>
<SO>British Journal of Surgery</SO>
<YR>1974</YR>
<VL>61</VL>
<NO>11</NO>
<PG>853-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MRC-1976" MODIFIED="2008-11-05 16:14:48 +0000" MODIFIED_BY="[Empty name]" NAME="MRC 1976" YEAR="1976">
<REFERENCE MODIFIED="2008-11-05 16:14:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Medical Research Council Working Party on tuberculosis of the spine</AU>
<TI>A five-year assessment of controlled trials of in-patient and out-patient treatment and of plaster-of-Paris jackets for tuberculosis of the spine in children on standard chemotherapy. Studies in Masan and Pusan, Korea. Fifth report of the Medical Research Council Working Party on tuberculosis of the spine</TI>
<SO>Journal of Bone and Joint Surgery</SO>
<YR>1976</YR>
<VL>58-B</VL>
<NO>4</NO>
<PG>399-411</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MRC-1978a" MODIFIED="2008-11-05 16:05:12 +0000" MODIFIED_BY="[Empty name]" NAME="MRC 1978a" YEAR="1978">
<REFERENCE MODIFIED="2008-11-05 16:05:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Medical Research Council Working Party on tuberculosis of the spine</AU>
<TI>A controlled trial of anterior spinal fusion and debridement in the surgical management of tuberculosis of the spine in patients on standard chemotherapy: a study in two centres in South Africa. Seventh Report of the Medical Research Council Working Party on tuberculosis of the spine</TI>
<SO>Tubercle</SO>
<YR>1978</YR>
<VL>59</VL>
<NO>2</NO>
<PG>79-105</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rauch RN</AU>
<TI>Proceedings: Spinal caries: surgical debridement versus radical resection and bonegrafting</TI>
<SO>Journal of Bone and Joint Surgery</SO>
<YR>1975</YR>
<VL>57-B</VL>
<NO>2</NO>
<PG>261-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MRC-1982" MODIFIED="2008-11-05 14:56:51 +0000" MODIFIED_BY="[Empty name]" NAME="MRC 1982" YEAR="1982">
<REFERENCE MODIFIED="2008-11-05 14:56:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Medical Research Council Working Party on Tuberculosis of the Spine</AU>
<TI>A 10-year assessment of a controlled trial comparing debridement and anterior spinal fusion in the management of tuberculosis of the spine in patients on standard chemotherapy in Hong Kong. Eighth Report of the Medical Research Council Working Party on Tuberculosis of the Spine</TI>
<SO>Journal of Bone and Joint Surgery</SO>
<YR>1982</YR>
<VL>64-B</VL>
<NO>4</NO>
<PG>393-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MRC-1985" MODIFIED="2008-11-05 16:09:27 +0000" MODIFIED_BY="[Empty name]" NAME="MRC 1985" YEAR="1985">
<REFERENCE MODIFIED="2008-11-05 16:09:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Medical Research Council Working Party on Tuberculosis of the Spine</AU>
<TI>A 10-year assessment of controlled trials of inpatient and outpatient treatment and of plaster-of-Paris jackets for tuberculosis of the spine in children on standard chemotherapy. Studies in Masan and Pusan, Korea. Ninth report of the Medical Research Council Working Party on Tuberculosis of the Spine</TI>
<SO>Journal of Bone and Joint Surgery</SO>
<YR>1985</YR>
<VL>67-B</VL>
<NO>1</NO>
<PG>103-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MRC-1986" MODIFIED="2008-11-05 16:16:45 +0000" MODIFIED_BY="[Empty name]" NAME="MRC 1986" YEAR="1986">
<REFERENCE MODIFIED="2008-11-05 16:16:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Medical Research Council Working Party on Tuberculosis of the Spine</AU>
<TI>Original Title:</TI>
<SO>Tubercle</SO>
<YR>1986</YR>
<VL>67</VL>
<NO>4</NO>
<PG>243-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MRC-1993" MODIFIED="2008-11-05 16:06:41 +0000" MODIFIED_BY="[Empty name]" NAME="MRC 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-11-05 16:06:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Medical Research Council Working Party on Tuberculosis of the Spine</AU>
<TI>Controlled trial of short-course regimens of chemotherapy in the ambulatory treatment of spinal tuberculosis. Results at three years of a study in Korea. Twelfth report of the Medical Research Council Working Party on Tuberculosis of the Spine</TI>
<SO>Journal of Bone and Joint Surgery</SO>
<YR>1993</YR>
<VL>75-B</VL>
<NO>2</NO>
<PG>240-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MRC-1998" MODIFIED="2008-11-05 16:12:53 +0000" MODIFIED_BY="[Empty name]" NAME="MRC 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-11-05 16:12:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Medical Research Council Working Party on Tuberculosis of the Spine</AU>
<TI>A 15-year assessment of controlled trials of the management of tuberculosis of the spine in Korea and Hong Kong. Thirteenth Report of the Medical Research Council Working Party on Tuberculosis of the Spine</TI>
<SO>Journal of Bone and Joint Surgery</SO>
<YR>1998</YR>
<VL>80-B</VL>
<NO>3</NO>
<PG>456-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rajasekaran-1998" NAME="Rajasekaran 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rajasekaran S, Shanmugasundaram TK, Prabhakar R, Dheenadhayalan J, Shetty AP, Shetty DK</AU>
<TI>Tuberculous lesions of the lumbosacral region. A 15-year follow-up of patients treated by ambulant chemotherapy</TI>
<SO>Spine</SO>
<YR>1998</YR>
<VL>23</VL>
<NO>10</NO>
<PG>1163-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rajeswari-1997b" NAME="Rajeswari 1997b" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rajeswari R, Balasubramanian R, Venkatesan P, Sivasubramanian S, Soundarapandian S, Shanmugasundaram TK, et al</AU>
<TI>Short-course chemotherapy in the treatment of Pott's paraplegia: report on five year follow-up</TI>
<SO>International Journal of Tuberculosis and Lung Disease</SO>
<YR>1997</YR>
<VL>1</VL>
<NO>2</NO>
<PG>152-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seddon-1976" NAME="Seddon 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seddon HJ</AU>
<TI>The choice of treatment in Pott's disease</TI>
<SO>Journal of Bone and Joint Surgery</SO>
<YR>1976</YR>
<VL>58-B</VL>
<NO>4</NO>
<PG>395-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Upadhyay-1993" NAME="Upadhyay 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Upadhyay SS, Sell P, Saji MJ, Sell B, Yau AC, Leong JC</AU>
<TI>17-year prospective study of surgical management of spinal tuberculosis in children. Hong Kong operation compared with debridement surgery for short- and long-term outcome of deformity</TI>
<SO>Spine</SO>
<YR>1993</YR>
<VL>18</VL>
<NO>12</NO>
<PG>1704-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Upadhyay-1994a" NAME="Upadhyay 1994a" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Upadhyay SS, Saji MJ, Sell P, Sell B, Hsu LC</AU>
<TI>Spinal deformity after childhood surgery for tuberculosis of the spine. A comparison of radical surgery and debridement</TI>
<SO>Journal of Bone and Joint Surgery</SO>
<YR>1994</YR>
<VL>76-B</VL>
<NO>1</NO>
<PG>91-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Upadhyay-1994b" NAME="Upadhyay 1994b" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Upadhyay SS, Saji MJ, Sell P, Sell B, Yau AC</AU>
<TI>Longitudinal changes in spinal deformity after anterior spinal surgery for tuberculosis of the spine in adults. A comparative analysis between radical and debridement surgery</TI>
<SO>Spine</SO>
<YR>1994</YR>
<VL>19</VL>
<NO>5</NO>
<PG>542-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Upadhyay-1994c" NAME="Upadhyay 1994c" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Upadhyay SS, Sell P, Saji MJ, Sell B, Hsu LC</AU>
<TI>Surgical management of spinal tuberculosis in adults. Hong Kong operation compared with debridement surgery for short and long term outcome of deformity</TI>
<SO>Clinical Orthopaedics and Related Research</SO>
<YR>1994</YR>
<VL>May</VL>
<NO>302</NO>
<PG>173-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Upadhyay-1996" NAME="Upadhyay 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Upadhyay SS, Saji MJ, Yau AC</AU>
<TI>Duration of antituberculosis chemotherapy in conjunction with radical surgery in the management of spinal tuberculosis</TI>
<SO>Spine</SO>
<YR>1996</YR>
<VL>21</VL>
<NO>16</NO>
<PG>1898-903</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-09 09:48:11 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-09 09:48:11 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Bass-1994" NAME="Bass 1994" TYPE="JOURNAL_ARTICLE">
<AU>Bass JB Jr, Farer LS, Hopewell PC, O'Brien R, Jacobs RF, Ruben F, et al</AU>
<TI>Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1994</YR>
<VL>149</VL>
<NO>5</NO>
<PG>1359-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boachie_x002d_Adjei-1996" NAME="Boachie-Adjei 1996" TYPE="JOURNAL_ARTICLE">
<AU>Boachie-Adjei O, Squillante RG</AU>
<TI>Tuberculosis of the spine</TI>
<SO>Orthopedic Clinics of North America</SO>
<YR>1996</YR>
<VL>27</VL>
<NO>1</NO>
<PG>95-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BTS-1998" NAME="BTS 1998" TYPE="JOURNAL_ARTICLE">
<TI>Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of the British Thoracic Society</TI>
<SO>Thorax</SO>
<YR>1998</YR>
<VL>53</VL>
<NO>7</NO>
<PG>536-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chen-1995" NAME="Chen 1995" TYPE="JOURNAL_ARTICLE">
<AU>Chen WJ, Chen CH, Shih CH</AU>
<TI>Surgical treatment of tuberculous spondylitis. 50 patients followed for 2-8 years</TI>
<SO>Acta Orthopaedica Scandinavica</SO>
<YR>1995</YR>
<VL>66</VL>
<NO>2</NO>
<PG>137-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fardon-2002" NAME="Fardon 2002" TYPE="BOOK">
<AU>Fardon DF, Garfin SR, editors</AU>
<SO>Orthopaedic knowledge update. Spine 2</SO>
<YR>2002</YR>
<EN>2nd</EN>
<PB>American Academy of Orthopaedic Surgeons</PB>
<CY>Rosemont, Ill</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Govender-2000" NAME="Govender 2000" TYPE="JOURNAL_ARTICLE">
<AU>Govender S, Annamalai K, Kumar KP, Govender UG</AU>
<TI>Spinal tuberculosis in HIV positive and negative patients: immunological response and clinical outcome</TI>
<SO>International Orthopaedics</SO>
<YR>2000</YR>
<VL>24</VL>
<NO>3</NO>
<PG>163-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-G_x00fc_ven-1994" NAME="Güven 1994" TYPE="JOURNAL_ARTICLE">
<AU>Güven O, Kumano K, Yalcin S, Karahan M, Tsuji S</AU>
<TI>A single stage posterior approach and rigid fixation for preventing kyphosis in the treatment of spinal tuberculosis</TI>
<SO>Spine</SO>
<YR>1994</YR>
<VL>19</VL>
<NO>9</NO>
<PG>1039-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" NAME="Higgins 2005" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]; Appendix 5b</TI>
<SO>www.cochrane.org/resources/handbook/hbook.htm</SO>
<YR>(accessed 1 October 2005)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hodgson-1960" NAME="Hodgson 1960" TYPE="JOURNAL_ARTICLE">
<AU>Hodgson AR, Stock FE</AU>
<TI>Anterior spine fusion for the treatment of tuberculosis of the spine. The operative findings and results of treatment in the first one hundred cases</TI>
<SO>Journal of Bone and Joint Surgery</SO>
<YR>1960</YR>
<VL>42A</VL>
<PG>295-310</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hsu-1988" NAME="Hsu 1988" TYPE="JOURNAL_ARTICLE">
<AU>Hsu LC, Cheng CL, Leong JC</AU>
<TI>Pott's paraplegia of late onset. The cause of compression and the results of anterior decompression</TI>
<SO>Journal of Bone and Joint Surgery</SO>
<YR>1988</YR>
<VL>70-B</VL>
<NO>4</NO>
<PG>534-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jellis-1996" NAME="Jellis 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jellis JE</AU>
<TI>Orthopaedic surgery and HIV disease in Africa</TI>
<SO>International Orthopaedics</SO>
<YR>1996</YR>
<VL>20</VL>
<NO>4</NO>
<PG>253-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jutte-2002" NAME="Jutte 2002" TYPE="JOURNAL_ARTICLE">
<AU>Jutte PC, Castelein RM</AU>
<TI>Complications of pedicle screws in lumbar and lumbosacral fusions in 105 consecutive primary operations</TI>
<SO>European Spine Journal</SO>
<YR>2002</YR>
<VL>11</VL>
<NO>6</NO>
<PG>594-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-J_x00fc_ni-2001" NAME="Jüni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Jüni P, Altman DG, Egger M</AU>
<TI>Systematic reviews in health care: Assessing the quality of controlled clinical trials</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<NO>7303</NO>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kaplan-1952" NAME="Kaplan 1952" TYPE="JOURNAL_ARTICLE">
<AU>Kaplan CJ</AU>
<TI>Pott's disease in South African Bantu children; an analysis of results and comparison with Lancashire figures</TI>
<SO>British Journal of Tuberculosis</SO>
<YR>1952</YR>
<VL>46</VL>
<NO>4</NO>
<PG>209-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Konstam-1958" NAME="Konstam 1958" TYPE="JOURNAL_ARTICLE">
<AU>Konstam PG, Konstam ST</AU>
<TI>Spinal tuberculosis in Southern Nigeria with special reference to ambulant treatment of thoracolumbar disease</TI>
<SO>Journal of Bone and Joint Surgery</SO>
<YR>1958</YR>
<VL>40-B</VL>
<NO>1</NO>
<PG>26-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Konstam-1962" NAME="Konstam 1962" TYPE="JOURNAL_ARTICLE">
<AU>Konstam PG, Blesovsky A</AU>
<TI>The ambulant treatment of spinal tuberculosis</TI>
<SO>British Journal of Surgery</SO>
<YR>1962</YR>
<VL>50</VL>
<PG>26-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lee-1999" NAME="Lee 1999" TYPE="JOURNAL_ARTICLE">
<AU>Lee TC, Lu K, Yang LC, Huang HY, Liang CL</AU>
<TI>Transpedicular instrumentation as an adjunct in the treatment of thoracolumbar and lumbar spine tuberculosis with early stage bone destruction</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1999</YR>
<VL>91</VL>
<NO>2 Suppl</NO>
<PG>163-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leibert-1996" NAME="Leibert 1996" TYPE="JOURNAL_ARTICLE">
<AU>Leibert E, Schluger NW, Bonk S, Rom WN</AU>
<TI>Spinal tuberculosis in patients with human immunodeficiency virus infection: clinical presentation, therapy and outcome</TI>
<SO>Tuberculosis and Lung Disease</SO>
<YR>1996</YR>
<VL>77</VL>
<NO>4</NO>
<PG>329-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leong-1993" NAME="Leong 1993" TYPE="JOURNAL_ARTICLE">
<AU>Leong JC</AU>
<TI>Tuberculosis of the spine</TI>
<SO>Journal of Bone and Joint Surgery</SO>
<YR>1993</YR>
<VL>75-B</VL>
<NO>2</NO>
<PG>173-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Luk-1999" NAME="Luk 1999" TYPE="JOURNAL_ARTICLE">
<AU>Luk KD</AU>
<TI>Tuberculosis of the spine in the new millenium</TI>
<SO>European Spine Journal</SO>
<YR>1999</YR>
<VL>8</VL>
<NO>5</NO>
<PG>338-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martini-1976" NAME="Martini 1976" TYPE="JOURNAL_ARTICLE">
<AU>Martini M, Hannachi MR, Ould M, Chaulet P</AU>
<TI>Chemotherapy in tuberculosis of the locomotor apparatus. Results in 252 cases</TI>
<SO>Acta Orthopaedica Belgica</SO>
<YR>1976</YR>
<VL>42</VL>
<NO>1</NO>
<PG>84-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moon-1995" NAME="Moon 1995" TYPE="JOURNAL_ARTICLE">
<AU>Moon MS, Woo YK, Lee KS, Ha KY, Kim SS, Sun DH</AU>
<TI>Posterior instrumentation and anterior interbody fusion for tuberculous kyphosis of dorsal and lumbar spines</TI>
<SO>Spine</SO>
<YR>1995</YR>
<VL>20</VL>
<NO>17</NO>
<PG>1910-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moon-1997" NAME="Moon 1997" TYPE="JOURNAL_ARTICLE">
<AU>Moon MS</AU>
<TI>Tuberculosis of the spine. Controversies and a new challenge</TI>
<SO>Spine</SO>
<YR>1997</YR>
<VL>22</VL>
<NO>15</NO>
<PG>1791-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MRC-1987" NAME="MRC 1987" TYPE="JOURNAL_ARTICLE">
<TI>Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Hong Kong Chest Service/British Medical Research Council</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1987</YR>
<VL>136</VL>
<NO>6</NO>
<PG>1139-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nene-2005" NAME="Nene 2005" TYPE="JOURNAL_ARTICLE">
<AU>Nene A, Bhojraj S</AU>
<TI>Results of nonsurgical treatment of thoracic spinal tuberculosis in adults</TI>
<SO>The Spine Journal</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>1</NO>
<PG>79-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nussbaum-1995" NAME="Nussbaum 1995" TYPE="JOURNAL_ARTICLE">
<AU>Nussbaum ES, Rockswold GL, Bergman TA, Erickson DL, Seljeskog EL</AU>
<TI>Spinal tuberculosis: a diagnostic and management challenge</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1995</YR>
<VL>83</VL>
<NO>2</NO>
<PG>243-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pattison-1986" NAME="Pattison 1986" TYPE="JOURNAL_ARTICLE">
<AU>Pattisson PR</AU>
<TI>Pott's paraplegia: an account of the treatment of 89 consecutive patients</TI>
<SO>Paraplegia</SO>
<YR>1986</YR>
<VL>24</VL>
<NO>2</NO>
<PG>77-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rajasekaran-1987" NAME="Rajasekaran 1987" TYPE="JOURNAL_ARTICLE">
<AU>Rajasekaran S, Shanmugasundaram TK</AU>
<TI>Prediction of the angle of gibbus deformity in tuberculosis of the spine</TI>
<SO>Journal of Bone and Joint Surgery</SO>
<YR>1987</YR>
<VL>69-B</VL>
<NO>4</NO>
<PG>503-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rajeswari-1997a" NAME="Rajeswari 1997a" TYPE="JOURNAL_ARTICLE">
<AU>Rajeswari R, Ranjani R, Santha T, Sriram K, Prabhakar R</AU>
<TI>Late onset paraplegia--a sequela to Pott's disease. A report on imaging, prevention and management</TI>
<SO>International Journal of Tuberculosis and Lung Disease</SO>
<YR>1997</YR>
<VL>1</VL>
<NO>5</NO>
<PG>468-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Review-Manager-5" MODIFIED="2008-11-09 09:48:11 +0000" MODIFIED_BY="[Empty name]" NAME="Review Manager 5" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<EN>5.0</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rezai-1995" NAME="Rezai 1995" TYPE="JOURNAL_ARTICLE">
<AU>Rezai AR, Lee M, Cooper PR, Errico TJ, Koslow M</AU>
<TI>Modern management of spinal tuberculosis</TI>
<SO>Neurosurgery</SO>
<YR>1995</YR>
<VL>36</VL>
<NO>1</NO>
<PG>87-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seddon-1935" NAME="Seddon 1935" TYPE="JOURNAL_ARTICLE">
<AU>Seddon HJ</AU>
<TI>Pott's paraplegia; prognosis and treatment</TI>
<SO>British Journal of Surgery</SO>
<YR>1935</YR>
<VL>22</VL>
<NO>88</NO>
<PG>769-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-1996" NAME="Smith 1996" TYPE="JOURNAL_ARTICLE">
<AU>Smith IE, Laroche CM, Jamieson SA, Shneerson JM</AU>
<TI>Kyphosis secondary to tuberculous osteomyelitis as a cause of ventilatory failure. Clinical features, mechanisms, and management</TI>
<SO>Chest</SO>
<YR>1996</YR>
<VL>110</VL>
<NO>4</NO>
<PG>1105-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sundararaj-2003" NAME="Sundararaj 2003" TYPE="JOURNAL_ARTICLE">
<AU>Sundararaj GD, Behera S, Ravi V, Venkatesh K, Cherian VM, Lee V</AU>
<TI>Role of posterior stabilisation in the management of tuberculosis of the dorsal and lumbar spine</TI>
<SO>Journal of Bone and Joint Surgery</SO>
<YR>2003</YR>
<VL>85-B</VL>
<NO>1</NO>
<PG>100-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tuli-1975" NAME="Tuli 1975" TYPE="JOURNAL_ARTICLE">
<AU>Tuli SM</AU>
<TI>Results of treatment of spinal tuberculosis by "middle-path" regime</TI>
<SO>Journal of Bone and Joint Surgery</SO>
<YR>1975</YR>
<VL>57-B</VL>
<NO>1</NO>
<PG>13-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Turgut-2001" NAME="Turgut 2001" TYPE="JOURNAL_ARTICLE">
<AU>Turgut M</AU>
<TI>Spinal tuberculosis (Pott's disease): its clinical presentation, surgical management, and outcome. A survey study on 694 patients</TI>
<SO>Neurosurgical Review</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>1</NO>
<PG>8-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Loenhout-2002" NAME="Van Loenhout 2002" TYPE="JOURNAL_ARTICLE">
<AU>Van Loenhout-Rooyackers JH, Verbeek AL, Jutte PC</AU>
<TI>Chemotherapeutic treatment for spinal tuberculosis</TI>
<SO>International Journal of Tuberculosis and Lung Disease</SO>
<YR>2002</YR>
<VL>6</VL>
<NO>3</NO>
<PG>259-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vidyasagar-1994" NAME="Vidyasagar 1994" TYPE="JOURNAL_ARTICLE">
<AU>Vidyasagar C, Murthy HK</AU>
<TI>Management of tuberculosis of the spine with neurological complications</TI>
<SO>Annals of the Royal College of Surgeons of England</SO>
<YR>1994</YR>
<VL>76</VL>
<NO>2</NO>
<PG>80-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Watts-1996" NAME="Watts 1996" TYPE="JOURNAL_ARTICLE">
<AU>Watts HG, Lifeso RM</AU>
<TI>Tuberculosis of bone and joints</TI>
<SO>Journal of Bone and Joint Surgery</SO>
<YR>1996</YR>
<VL>78-A</VL>
<NO>2</NO>
<PG>288-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2005" NAME="WHO 2005" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Global TB database</TI>
<SO>www.who.int/tb/country/global_tb_database/en/index.html</SO>
<YR>(accessed August 2005)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wimmer-1997" NAME="Wimmer 1997" TYPE="JOURNAL_ARTICLE">
<AU>Wimmer C, Ogon M, Sterzinger W, Landauer F, Stöckl B</AU>
<TI>Conservative treatment of tuberculous spondylitis: a long-term follow-up study</TI>
<SO>Journal of Spinal Disorders</SO>
<YR>1997</YR>
<VL>10</VL>
<NO>5</NO>
<PG>417-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-_x00d6_zdemir-2003" NAME="Özdemir 2003" TYPE="JOURNAL_ARTICLE">
<AU>Özdemir HM, Us AK, Ogun T</AU>
<TI>The role of anterior spinal instrumentation and allograft fibula for the treatment of pott disease</TI>
<SO>Spine</SO>
<YR>2003</YR>
<VL>28</VL>
<NO>5</NO>
<PG>474-9</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-11-09 13:04:32 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-11-09 13:04:32 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-11-09 13:04:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ICMR_x002f_MRC-1989">
<CHAR_METHODS>
<P>Randomized controlled trial</P>
<P>Generation of allocation sequence: unclear</P>
<P>Allocation concealment: sealed envelopes</P>
<P>Blinding: assessor only</P>
<P>Inclusion of all randomized (enrolled) participants in the final analysis for primary outcomes:<BR/>1. Deformity: 73/130 (56%) at 3 years (73/94 available as x-rays technically inadequate or x-ray series incomplete for 21 participants); 65/130 (50%) at 5 years (15 participants not assessed for x-rays not being available on 0 or 60 months follow up)<BR/>2. Neurology: 68% (89/130) at 3 years; 62% (80/130) at 5 years; 5 participants excluded for neurological assessment (2 died of nontuberculous causes and 3 defaulted, all after 18 months)</P>
<P>Length of follow up: 5 years, with assessment at 18 months, 3 years, and 5 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-09 13:04:32 +0000" MODIFIED_BY="[Empty name]">
<P>Number (further details in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>): 201 enrolled and randomized</P>
<P>168 available for analysis at 3 years; losses to follow up due to no tuberculosis (3), refused surgery (2), considered unfit for the anaesthetic (1), considered unfit for surgery (3), no evidence of active spinal tuberculosis on radiographs (7), defaulted from 4 to 25 months (1), died of nontuberculous causes (6), operated at wrong level (1), missed considerable amount (&gt; 6 weeks) of chemotherapy (9)</P>
<P>164 available for analysis at 5 years; losses to follow up due to reasons detailed above (33), excluded due to death of unrelated cause, default, or additional chemotherapy due to tuberculosis in other location (4; no details given)</P>
<P>156 available for analysis at 10 years; losses to follow up due to reasons detailed above during 0 to 5 years (37), and excluded for nontuberculous death (4) or default from follow up (4)</P>
<P>Inclusion criteria: presence of clinical and radiographic evidence of tuberculosis of any vertebral body from the first thoracic to the first sacral, inclusive, that is excluding cervical and sacral disease; disease was active clinically and/or radiographically (radiographic active disease: (a) loss of the thin cortical outline and (b) rarefaction of the affected vertebral bodies); availability for observation over a period of 3 years</P>
<P>Exclusion criteria: paraplegia or paraparesis severe enough to prevent walking; active tuberculosis in a lower limb requiring rest in bed; pulmonary tuberculosis of a type considered likely to complicate the management; history of previous antituberculosis chemotherapy for 12 months or more; serious nontuberculous disease likely to prejudice the response to treatment or its assessment; contraindication to the methods of the treatment under comparison</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-09 09:41:02 +0000" MODIFIED_BY="[Empty name]">
<P>1. Chemotherapy<BR/>Adults (&#8805; 45 kg): daily streptomycin sulphate (1 g) by intramuscular injection for the first 3 months plus isoniazid (300 mg) and sodium p-amino salicylic acid (PAS) (10 g), both for 18 months</P>
<P>Children (&lt; 15 years) and adults (&lt; 45 kg): daily streptomycin sulphate (20 mg/kg bodyweight) by intramuscular injection for the first 3 months plus isoniazid (6 mg/kg bodyweight; maximum 300 mg) and sodium PAS (0.2 mg/kg bodyweight; maximum 10 g), both for 18 months</P>
<P>Participants randomized to this regimen or the same regimen without the initial 3 months of streptomycin</P>
<P>2. Chemotherapy plus debridement surgery<BR/>Same chemotherapy regimen with debridement surgery: an operation to remove all necrotic and diseased tissue without reconstruction</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Kyphosis angle<BR/>2. Neurological deficit<BR/>3. Bony fusion<BR/>4. Absence of spinal tuberculosis<BR/>5. Deaths from any cause<BR/>6. Regained activity level<BR/>7. Change of allocated treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-05 13:55:38 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Bulawayo, Rhodesia (now Zimbabwe)</P>
<P>Date: 3-year follow up in 1974; 5-year follow up in 1978</P>
<P>The 5-year report contains information about a study from Hong Kong performed by the same group of investigators, the British Medical Research Council (MRC), with the same criteria; we excluded this part of the report from the analysis because participants were not randomized between chemotherapy or chemotherapy plus surgery</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-09 13:04:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-MRC-1974a">
<CHAR_METHODS>
<P>Randomized controlled trial</P>
<P>Generation of allocation sequence: unclear</P>
<P>Allocation concealment: sealed envelopes</P>
<P>Blinding: assessor only</P>
<P>Inclusion of all randomized (enrolled) participants in the final analysis for primary outcomes: <BR/>1. Deformity: 39% (79/201) at 5 years; 34% (69/201) at 10 years; not available at 3 years; lumbar lesions excluded for deformity measurements, so total number less than 201, and, as a consequence, the percentages are higher than 39% and 34%, but exact figures cannot be reconstructed from article<BR/>2. Neurology: 80% (161/201) at 5 years; 78% (156/201) at 10 years; not available at 3 years</P>
<P>Length of follow up: 10 years, with assessment at 18 months, and 3, 5, and 10 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-09 13:04:32 +0000" MODIFIED_BY="[Empty name]">
<P>Number (further details in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>): 130 enrolled and randomized</P>
<P>94 available for analysis at 3 years, 36 lost to follow up due to no evidence on radiographs of tuberculosis (5), permanent default (6), excessive interruption (17), major drug change (3 toxicity, 1 brucellosis), death nontuberculous cause (3), admitted in error 1)</P>
<P>80 available for analysis at 5 years, 50 lost to follow up due to earlier exclusion (36 at 3 years), defaulted from follow up between 3 and 5 years (6), died of unrelated cause (3), not explained (5)</P>
<P>Inclusion criteria: presence of clinical and radiographic evidence of tuberculosis of any vertebral body from the first thoracic to the first sacral, inclusive, that is excluding cervical and sacral disease; disease was active clinically and/or radiographically (radiographic active disease: (a) loss of the thin cortical outline and (b) rarefaction of the affected vertebral bodies); availability for observation over a period of 3 years</P>
<P>Exclusion criteria: paraplegia or paraparesis severe enough to prevent walking; active tuberculosis in a lower limb requiring rest in bed; pulmonary tuberculosis of a type considered likely to complicate the management; a history of previous antituberculosis chemotherapy for 12 months or more; serious nontuberculous disease likely to prejudice the response to treatment or its assessment; a contraindication to the methods of the treatment under comparison</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-05 13:58:59 +0000" MODIFIED_BY="[Empty name]">
<P>1. Chemotherapy<BR/>Isoniazid plus rifampicin (1 dose daily for 6 months)<BR/>2. Chemotherapy plus surgery<BR/>Isoniazid plus rifampicin (1 dose daily for 6 months) with an operation consisting of debridement (removal of all necrotic and diseased tissue) and stabilization with a bone graft (reconstruction)</P>
<P>Not included in review because it has a different chemotherapy regimen without a comparable surgical intervention group:</P>
<P>3. Chemotherapy<BR/>Isoniazid plus rifampicin (1 dose daily for 9 months)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Kyphosis angle<BR/>2. Neurological deficit<BR/>3. Bony fusion<BR/>4. Absence of spinal tuberculosis<BR/>5. Deaths from any cause<BR/>6. Regained activity level<BR/>7. Change of allocated treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-05 13:59:34 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Madras, India</P>
<P>Date: 3-year follow up in 1989; 5-year follow up in 1999; and 10-year follow up in 1999</P>
<P>The 5-year report also includes information from studies done in Hong Kong (all surgical) and Korea (all chemotherapy); we excluded these results from analysis because they did not randomize between chemotherapy alone and chemotherapy plus surgery</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-11-09 09:41:47 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Jain-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Loembe-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-MRC-1973a">
<CHAR_REASON_FOR_EXCLUSION>
<P>No surgical group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-MRC-1973b">
<CHAR_REASON_FOR_EXCLUSION>
<P>No surgical group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-MRC-1974b">
<CHAR_REASON_FOR_EXCLUSION>
<P>All participants had surgery</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-MRC-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>No surgical group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-MRC-1978a">
<CHAR_REASON_FOR_EXCLUSION>
<P>All participants had surgery</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-MRC-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>All participants had surgery</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-MRC-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>No surgical group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-MRC-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>All participants had surgery</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-MRC-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>No surgical group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-MRC-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomization for conservative or surgical treatment: 2 locations, Korea (all chemotherapy without surgery) and Hong Kong (all chemotherapy plus surgery)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rajasekaran-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>No surgical group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-09 09:41:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rajeswari-1997b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-09 09:41:47 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized controlled trial, poor methodological quality, randomization method and concealment are unclear; study reports on 33 participants of whom the first 10 were not randomized but all operated because of participation in another trial (one of the included trials <LINK REF="STD-ICMR_x002f_MRC-1989" TYPE="STUDY">ICMR/MRC 1989</LINK>); the other 23 patients were allocated to chemotherapy only, 4 were lost to follow up for various reasons; of the 19 included in the analysis 3 were operated for neurological deterioration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Seddon-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Description of several MRC studies, not a study itself</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Upadhyay-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>All participants had surgery</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Upadhyay-1994a">
<CHAR_REASON_FOR_EXCLUSION>
<P>All participants had surgery</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Upadhyay-1994b">
<CHAR_REASON_FOR_EXCLUSION>
<P>All participants had surgery</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Upadhyay-1994c">
<CHAR_REASON_FOR_EXCLUSION>
<P>All participants had surgery</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Upadhyay-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>All participants had surgery</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-11-09 09:38:39 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-11-09 09:38:39 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-11-09 13:04:18 +0000" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Chemotherapy plus surgery versus chemotherapy alone</NAME>
<DICH_OUTCOME CHI2="2.2864862462113584" CI_END="1.272042558769082" CI_START="0.4409342023910057" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7489239421051107" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.1045016417600143" LOG_CI_START="-0.35562621250601434" LOG_EFFECT_SIZE="-0.12556228537300004" METHOD="MH" NO="1" P_CHI2="0.8915563415419826" P_Q="0.9672170275907088" P_Z="0.2847579555815285" Q="0.2608393376722316" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="469" TOTAL_2="455" WEIGHT="400.0" Z="1.0696920643510364">
<NAME>Change of allocated treatment</NAME>
<GROUP_LABEL_1>Chemo + surgery</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chemo+surg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chemotherapy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.4170820408774827" CI_END="2.0859678741864602" CI_START="0.2720811647747144" DF="1" EFFECT_SIZE="0.7533608490566038" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.31930761560969534" LOG_CI_START="-0.5653015218642627" LOG_EFFECT_SIZE="-0.1229969531272837" NO="1" P_CHI2="0.5183966686014101" P_Z="0.585732359643022" STUDIES="2" TAU2="0.0" TOTAL_1="132" TOTAL_2="130" WEIGHT="100.0" Z="0.5450307669803695">
<NAME>At 18 months</NAME>
<DICH_DATA CI_END="3.500493980809378" CI_START="0.2715688143477962" EFFECT_SIZE="0.975" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5441293352079274" LOG_CI_START="-0.5661201038108539" LOG_EFFECT_SIZE="-0.010995384301463193" ORDER="1" O_E="0.0" SE="0.6521660163029908" STUDY_ID="STD-ICMR_x002f_MRC-1989" TOTAL_1="85" TOTAL_2="83" VAR="0.42532051282051286" WEIGHT="55.424528301886795"/>
<DICH_DATA CI_END="2.744157212361234" CI_START="0.08318459449407903" EFFECT_SIZE="0.4777777777777778" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.43840898841414533" LOG_CI_START="-1.079957096133622" LOG_EFFECT_SIZE="-0.32077405385973834" ORDER="2" O_E="0.0" SE="0.8918957540966941" STUDY_ID="STD-MRC-1974a" TOTAL_1="47" TOTAL_2="47" VAR="0.7954780361757107" WEIGHT="44.57547169811321"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7884458695963621" CI_END="1.8243941821262293" CI_START="0.24853477989524875" DF="1" EFFECT_SIZE="0.673368700265252" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.26111867863439964" LOG_CI_START="-0.6046128276161088" LOG_EFFECT_SIZE="-0.17174707449085458" NO="2" P_CHI2="0.3745705212451138" P_Z="0.4367753451938222" STUDIES="2" TAU2="0.0" TOTAL_1="132" TOTAL_2="130" WEIGHT="100.0" Z="0.7776500636094187">
<NAME>At 3 years</NAME>
<DICH_DATA CI_END="3.500493980809378" CI_START="0.2715688143477962" EFFECT_SIZE="0.975" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5441293352079274" LOG_CI_START="-0.5661201038108539" LOG_EFFECT_SIZE="-0.010995384301463193" ORDER="3" O_E="0.0" SE="0.6521660163029908" STUDY_ID="STD-ICMR_x002f_MRC-1989" TOTAL_1="85" TOTAL_2="83" VAR="0.42532051282051286" WEIGHT="49.86737400530504"/>
<DICH_DATA CI_END="2.029112738137151" CI_START="0.06868902607438909" EFFECT_SIZE="0.37333333333333335" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.30730617724067966" LOG_CI_START="-1.163112641339641" LOG_EFFECT_SIZE="-0.42790323204948083" ORDER="4" O_E="0.0" SE="0.8637312927246217" STUDY_ID="STD-MRC-1974a" TOTAL_1="47" TOTAL_2="47" VAR="0.7460317460317462" WEIGHT="50.13262599469496"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8459397180975484" CI_END="1.9157662609701847" CI_START="0.2516084457830719" DF="1" EFFECT_SIZE="0.6942787418655096" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="0.282342520523726" LOG_CI_START="-0.5992747849460798" LOG_EFFECT_SIZE="-0.15846613221117695" NO="3" P_CHI2="0.3577035926179375" P_Z="0.48106748564747803" STUDIES="2" TAU2="0.0" TOTAL_1="127" TOTAL_2="117" WEIGHT="100.0" Z="0.7045866953298063">
<NAME>At 5 years</NAME>
<DICH_DATA CI_END="3.5937762620734808" CI_START="0.27825883613106056" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5555510357191101" LOG_CI_START="-0.5555510357191101" LOG_EFFECT_SIZE="0.0" ORDER="5" O_E="0.0" SE="0.6526668568067678" STUDY_ID="STD-ICMR_x002f_MRC-1989" TOTAL_1="82" TOTAL_2="82" VAR="0.425974025974026" WEIGHT="52.19631236442516"/>
<DICH_DATA CI_END="2.093245880017065" CI_START="0.06207350091763896" EFFECT_SIZE="0.36046511627906974" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.3208202450910727" LOG_CI_START="-1.207093759909663" LOG_EFFECT_SIZE="-0.4431367574092951" ORDER="6" O_E="0.0" SE="0.8975042498337361" STUDY_ID="STD-MRC-1974a" TOTAL_1="45" TOTAL_2="35" VAR="0.8055138784696174" WEIGHT="47.80368763557483"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.601457927827942" CI_START="0.2776653288861562" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="0.5564783457213741" LOG_CI_START="-0.5564783457213741" LOG_EFFECT_SIZE="0.0" NO="4" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="78" WEIGHT="100.0" Z="0.0">
<NAME>At 10 years</NAME>
<DICH_DATA CI_END="3.601457927827942" CI_START="0.2776653288861562" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5564783457213741" LOG_CI_START="-0.5564783457213741" LOG_EFFECT_SIZE="0.0" ORDER="7" O_E="0.0" SE="0.6537562697779445" STUDY_ID="STD-ICMR_x002f_MRC-1989" TOTAL_1="78" TOTAL_2="78" VAR="0.4273972602739726" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.16199299603937353" CI_END="1.7283100232415436" CI_START="0.5821678317448046" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="1.003078510792322" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="47" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.23762164862111276" LOG_CI_START="-0.23495179560228094" LOG_EFFECT_SIZE="0.0013349265094159135" METHOD="MH" NO="2" P_CHI2="0.9221969481103495" P_Q="0.7227400438855898" P_Z="0.9911651878938743" Q="0.12588252470929745" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="107" TOTAL_2="115" WEIGHT="200.0" Z="0.011073021188326183">
<NAME>Clinically significant increase in kyphosis angle</NAME>
<GROUP_LABEL_1>Chemo + surgery</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chemo+surg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chemotherapy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.920098681716402E-32" CI_END="2.15758948998511" CI_START="0.36072041144262157" DF="0" EFFECT_SIZE="0.882205513784461" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="21" I2="100.0" ID="CMP-001.02.01" LOG_CI_END="0.3339688179217589" LOG_CI_START="-0.44282928233899344" LOG_EFFECT_SIZE="-0.05443023220861729" NO="1" P_CHI2="0.0" P_Z="0.7835703204819441" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="43" WEIGHT="100.0" Z="0.27466929891623476">
<NAME>Deterioration &gt; 10 ° at 3 years</NAME>
<DICH_DATA CI_END="2.15758948998511" CI_START="0.36072041144262157" EFFECT_SIZE="0.8822055137844611" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="21" LOG_CI_END="0.3339688179217589" LOG_CI_START="-0.44282928233899344" LOG_EFFECT_SIZE="-0.05443023220861724" ORDER="8" O_E="0.0" SE="0.456295049305777" STUDY_ID="STD-ICMR_x002f_MRC-1989" TOTAL_1="35" TOTAL_2="43" VAR="0.2082051720209615" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.03639022103699893" CI_END="2.149130699888116" CI_START="0.5446665822441027" DF="1" EFFECT_SIZE="1.0819240606918474" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="26" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.3322628280154799" LOG_CI_START="-0.2638692698383022" LOG_EFFECT_SIZE="0.034196779088588834" NO="2" P_CHI2="0.8487119652895896" P_Z="0.8220847332099758" STUDIES="2" TAU2="0.0" TOTAL_1="72" TOTAL_2="72" WEIGHT="100.0" Z="0.2248644407580488">
<NAME>Deterioration &gt; 10 ° at 5 years</NAME>
<DICH_DATA CI_END="2.5517983849840244" CI_START="0.40739901706361226" EFFECT_SIZE="1.0196078431372548" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="17" LOG_CI_END="0.4068463582357074" LOG_CI_START="-0.38998002316198194" LOG_EFFECT_SIZE="0.008433167536862764" ORDER="9" O_E="0.0" SE="0.46805976078720435" STUDY_ID="STD-ICMR_x002f_MRC-1989" TOTAL_1="34" TOTAL_2="45" VAR="0.21907993966817496" WEIGHT="57.62497206287715"/>
<DICH_DATA CI_END="3.289794470805261" CI_START="0.4137374304656621" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.517168766344095" LOG_CI_START="-0.3832751870828686" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="10" O_E="0.0" SE="0.5289252355124539" STUDY_ID="STD-MRC-1974a" TOTAL_1="38" TOTAL_2="27" VAR="0.27976190476190477" WEIGHT="42.37502793712285"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.519939144700507" CI_END="4.800076616113886" CI_START="0.6971646069021014" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="1.8293287094377013" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.6812481693943235" LOG_CI_START="-0.15666466891901557" LOG_EFFECT_SIZE="0.26229175023765394" METHOD="MH" NO="3" P_CHI2="0.4790503111157908" P_Q="0.6776533946352377" P_Z="0.21980210876235895" Q="1.5200379590035287" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="38" TOTAL_2="38" WEIGHT="400.0" Z="1.2270545584254073">
<NAME>Improvement in neurological deficit</NAME>
<GROUP_LABEL_1>Chemo + surgery</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chemotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chemo+surg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.057134286330138756" CI_END="21.66816402194177" CI_START="0.46522746411703764" DF="1" EFFECT_SIZE="3.1750000000000003" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="1.335822114415378" LOG_CI_START="-0.3323346551593889" LOG_EFFECT_SIZE="0.5017437296279945" NO="1" P_CHI2="0.811084032878243" P_Z="0.23838806437783078" STUDIES="2" TAU2="0.0" TOTAL_1="11" TOTAL_2="12" WEIGHT="100.00000000000001" Z="1.17902544590021">
<NAME>At 18 months</NAME>
<DICH_DATA CI_END="60.324699402210776" CI_START="0.26523132578450337" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="1.7804951664981645" LOG_CI_START="-0.5763751838422398" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="11" O_E="0.0" SE="1.3844373104863457" STUDY_ID="STD-ICMR_x002f_MRC-1989" TOTAL_1="5" TOTAL_2="6" VAR="1.9166666666666665" WEIGHT="45.00000000000001"/>
<DICH_DATA CI_END="38.599197557931376" CI_START="0.16192046455421064" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="1.5865782761799185" LOG_CI_START="-0.7906982588358433" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="12" O_E="0.0" SE="1.396424004376894" STUDY_ID="STD-MRC-1974a" TOTAL_1="6" TOTAL_2="6" VAR="1.95" WEIGHT="55.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0439524789132313" CI_END="10.192415583326852" CI_START="0.3311617342284548" DF="1" EFFECT_SIZE="1.8372093023255813" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="4.210199199774535" ID="CMP-001.03.02" LOG_CI_END="1.0082771231806427" LOG_CI_START="-0.47995985175893313" LOG_EFFECT_SIZE="0.2641586357108549" NO="2" P_CHI2="0.30690435170347174" P_Z="0.4865677565187747" STUDIES="2" TAU2="0.0" TOTAL_1="11" TOTAL_2="12" WEIGHT="100.0" Z="0.6957781870989096">
<NAME>At 3 years</NAME>
<DICH_DATA CI_END="8.833504821968539" CI_START="0.0636780090503927" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.946133050444887" LOG_CI_START="-1.1960105236614869" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="13" O_E="0.0" SE="1.2583057392117916" STUDY_ID="STD-ICMR_x002f_MRC-1989" TOTAL_1="5" TOTAL_2="6" VAR="1.5833333333333333" WEIGHT="74.4186046511628"/>
<DICH_DATA CI_END="72.76670532259351" CI_START="0.34356372037415417" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="1.8619327117002133" LOG_CI_START="-0.4639927030281758" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="14" O_E="0.0" SE="1.3662601021279464" STUDY_ID="STD-MRC-1974a" TOTAL_1="6" TOTAL_2="6" VAR="1.8666666666666665" WEIGHT="25.58139534883721"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.878569031110789" CI_END="13.134985574455486" CI_START="0.34958825867490395" DF="1" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" I2="65.26051697241675" ID="CMP-001.03.03" LOG_CI_END="1.1184296001568952" LOG_CI_START="-0.45644316207404656" LOG_EFFECT_SIZE="0.3309932190414244" NO="3" P_CHI2="0.08976588931966101" P_Z="0.41002095775143765" STUDIES="2" TAU2="0.0" TOTAL_1="11" TOTAL_2="9" WEIGHT="100.0" Z="0.8238567635510831">
<NAME>At 5 years</NAME>
<DICH_DATA CI_END="8.459133870491831" CI_START="0.008792881922429198" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.9273258979654306" LOG_CI_START="-2.055868758842556" LOG_EFFECT_SIZE="-0.5642714304385626" ORDER="15" O_E="0.0" SE="1.7523433084607225" STUDY_ID="STD-ICMR_x002f_MRC-1989" TOTAL_1="5" TOTAL_2="5" VAR="3.070707070707071" WEIGHT="87.3015873015873"/>
<DICH_DATA CI_END="339.5484973850903" CI_START="0.6626446641135386" EFFECT_SIZE="15.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="2.530901812909648" LOG_CI_START="-0.1787192947982856" LOG_EFFECT_SIZE="1.1760912590556813" ORDER="16" O_E="0.0" SE="1.591644851508443" STUDY_ID="STD-MRC-1974a" TOTAL_1="6" TOTAL_2="4" VAR="2.5333333333333337" WEIGHT="12.6984126984127"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.459133870491831" CI_START="0.008792881922429198" DF="0" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-001.03.04" LOG_CI_END="0.9273258979654306" LOG_CI_START="-2.055868758842556" LOG_EFFECT_SIZE="-0.5642714304385626" NO="4" P_CHI2="1.0" P_Z="0.4584178630625805" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.00000000000001" Z="0.741454587041831">
<NAME>At 10 years</NAME>
<DICH_DATA CI_END="8.459133870491831" CI_START="0.008792881922429198" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.9273258979654306" LOG_CI_START="-2.055868758842556" LOG_EFFECT_SIZE="-0.5642714304385626" ORDER="17" O_E="0.0" SE="1.7523433084607225" STUDY_ID="STD-ICMR_x002f_MRC-1989" TOTAL_1="5" TOTAL_2="5" VAR="3.070707070707071" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.985631646734416" CI_END="1.2675465784300806" CI_START="0.7123426630688832" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9502249761202526" ESTIMABLE="YES" EVENTS_1="292" EVENTS_2="287" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.10296392728228321" LOG_CI_START="-0.14731104445152277" LOG_EFFECT_SIZE="-0.022173558584619772" METHOD="MH" NO="4" P_CHI2="0.6786211521440308" P_Q="0.7003389149073538" P_Z="0.7283711895992938" Q="1.4222016331583887" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="454" TOTAL_2="441" WEIGHT="400.0" Z="0.34729302681665963">
<NAME>Bony fusion</NAME>
<GROUP_LABEL_1>Chemo + surgery</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chemotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chemo+surg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6535494317893505" CI_END="1.5908727914239293" CI_START="0.5924868743344612" DF="1" EFFECT_SIZE="0.9708610856628785" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="57" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.20163545419632684" LOG_CI_START="-0.22732126635964134" LOG_EFFECT_SIZE="-0.012842906081657255" NO="1" P_CHI2="0.41884679673508474" P_Z="0.9065731066609624" STUDIES="2" TAU2="0.0" TOTAL_1="128" TOTAL_2="128" WEIGHT="100.0" Z="0.1173621121695161">
<NAME>At 18 months</NAME>
<DICH_DATA CI_END="2.090470505049864" CI_START="0.6101100350653444" EFFECT_SIZE="1.1293436293436294" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="37" LOG_CI_END="0.32024404436457093" LOG_CI_START="-0.21459183169067608" LOG_EFFECT_SIZE="0.052826106336947454" ORDER="18" O_E="0.0" SE="0.3141652410751366" STUDY_ID="STD-ICMR_x002f_MRC-1989" TOTAL_1="81" TOTAL_2="82" VAR="0.0986997986997987" WEIGHT="59.64047837175328"/>
<DICH_DATA CI_END="1.6944355972195764" CI_START="0.32027052469168227" EFFECT_SIZE="0.7366666666666667" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="20" LOG_CI_END="0.22902506665011965" LOG_CI_START="-0.49448302871922317" LOG_EFFECT_SIZE="-0.13272898103455172" ORDER="19" O_E="0.0" SE="0.42499223664278446" STUDY_ID="STD-MRC-1974a" TOTAL_1="47" TOTAL_2="46" VAR="0.1806184012066365" WEIGHT="40.35952162824671"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8996770745034826" CI_END="1.2676059014748384" CI_START="0.451023923031852" DF="1" EFFECT_SIZE="0.7561220711905644" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="80" I2="47.35947422740945" ID="CMP-001.04.02" LOG_CI_END="0.10298425242737563" LOG_CI_START="-0.3458004218356154" LOG_EFFECT_SIZE="-0.12140808470411987" NO="2" P_CHI2="0.16811469907854248" P_Z="0.28894273864729325" STUDIES="2" TAU2="0.0" TOTAL_1="126" TOTAL_2="121" WEIGHT="100.00000000000001" Z="1.0604438480117062">
<NAME>At 3 years</NAME>
<DICH_DATA CI_END="1.8537472085760744" CI_START="0.5188993836773153" EFFECT_SIZE="0.9807692307692307" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="52" LOG_CI_END="0.26805051006426295" LOG_CI_START="-0.2849168451379886" LOG_EFFECT_SIZE="-0.008433167536862813" ORDER="20" O_E="0.0" SE="0.32481576167835635" STUDY_ID="STD-ICMR_x002f_MRC-1989" TOTAL_1="81" TOTAL_2="82" VAR="0.10550527903469079" WEIGHT="57.75638652350982"/>
<DICH_DATA CI_END="1.1162104149357168" CI_START="0.18059558591154173" EFFECT_SIZE="0.4489795918367347" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="28" LOG_CI_END="0.04774607043651803" LOG_CI_START="-0.7432928688491328" LOG_EFFECT_SIZE="-0.34777339920630745" ORDER="21" O_E="0.0" SE="0.4646601886422925" STUDY_ID="STD-MRC-1974a" TOTAL_1="45" TOTAL_2="39" VAR="0.21590909090909088" WEIGHT="42.2436134764902"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.04842436985121604" CI_END="2.0005045857258947" CI_START="0.5704414249578377" DF="1" EFFECT_SIZE="1.0682559087204564" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="89" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="0.3011395512427186" LOG_CI_START="-0.2437889439252052" LOG_EFFECT_SIZE="0.02867530365875667" NO="3" P_CHI2="0.8258280263432602" P_Z="0.8365761065658339" STUDIES="2" TAU2="0.0" TOTAL_1="122" TOTAL_2="114" WEIGHT="100.0" Z="0.2062749990697164">
<NAME>At 5 years</NAME>
<DICH_DATA CI_END="2.356112532162819" CI_START="0.5301677789346627" EFFECT_SIZE="1.1176470588235294" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="60" LOG_CI_END="0.3721960292942749" LOG_CI_START="-0.27558667014516486" LOG_EFFECT_SIZE="0.048304679574555046" ORDER="22" O_E="0.0" SE="0.3805107642268041" STUDY_ID="STD-ICMR_x002f_MRC-1989" TOTAL_1="77" TOTAL_2="79" VAR="0.14478844169246646" WEIGHT="69.27465362673186"/>
<DICH_DATA CI_END="3.0670621845064154" CI_START="0.29854334722231984" EFFECT_SIZE="0.9568965517241379" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="29" LOG_CI_END="0.4867225813669712" LOG_CI_START="-0.5249926022474934" LOG_EFFECT_SIZE="-0.019135010440261058" ORDER="23" O_E="0.0" SE="0.5942865069260646" STUDY_ID="STD-MRC-1974a" TOTAL_1="45" TOTAL_2="35" VAR="0.3531764523143833" WEIGHT="30.725346373268135"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8058147506277606" CI_START="0.5784729494650442" DF="0" EFFECT_SIZE="1.2740046838407495" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="61" I2="0.0" ID="CMP-001.04.04" LOG_CI_END="0.4480589940494461" LOG_CI_START="-0.23771694470313393" LOG_EFFECT_SIZE="0.10517102467315607" NO="4" P_CHI2="1.0" P_Z="0.5477317002410776" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="78" WEIGHT="100.0" Z="0.6011625924103153">
<NAME>At 10 years</NAME>
<DICH_DATA CI_END="2.8058147506277606" CI_START="0.5784729494650442" EFFECT_SIZE="1.2740046838407495" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="61" LOG_CI_END="0.4480589940494461" LOG_CI_START="-0.23771694470313393" LOG_EFFECT_SIZE="0.10517102467315607" ORDER="24" O_E="0.0" SE="0.4028281810689105" STUDY_ID="STD-ICMR_x002f_MRC-1989" TOTAL_1="78" TOTAL_2="78" VAR="0.16227054346328695" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.952364982599071" CI_END="1.6406365158808018" CI_START="0.7781035302648158" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1298606395871216" ESTIMABLE="YES" EVENTS_1="401" EVENTS_2="382" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.21501237347671548" LOG_CI_START="-0.10896261428107634" LOG_EFFECT_SIZE="0.053024879597819555" METHOD="MH" NO="5" P_CHI2="0.6831229895557633" P_Q="0.6897360459244843" P_Z="0.5211502643193928" Q="1.4677385377068035" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="469" TOTAL_2="454" WEIGHT="400.0" Z="0.6415733203082715">
<NAME>Absence of spinal tuberculosis</NAME>
<GROUP_LABEL_1>Chemo + surgery</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chemotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chemo + surg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.008375804584061243" CI_END="2.0453225955428813" CI_START="0.6678446622896764" DF="1" EFFECT_SIZE="1.1687419638627596" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="92" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.31076181621374144" LOG_CI_START="-0.17532454075130177" LOG_EFFECT_SIZE="0.06771863773121986" NO="1" P_CHI2="0.9270798749625239" P_Z="0.5849966047267604" STUDIES="2" TAU2="0.0" TOTAL_1="132" TOTAL_2="129" WEIGHT="100.0" Z="0.546100869252955">
<NAME>At 18 months</NAME>
<DICH_DATA CI_END="2.177638420116199" CI_START="0.6097315232300147" EFFECT_SIZE="1.1522911051212938" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="53" LOG_CI_END="0.33798577019268433" LOG_CI_START="-0.21486135129439313" LOG_EFFECT_SIZE="0.06156220944914559" ORDER="25" O_E="0.0" SE="0.3247451357988965" STUDY_ID="STD-ICMR_x002f_MRC-1989" TOTAL_1="85" TOTAL_2="83" VAR="0.10545940322504374" WEIGHT="77.83041212695406"/>
<DICH_DATA CI_END="3.972567359051155" CI_START="0.3786699207717346" EFFECT_SIZE="1.2264957264957266" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="39" LOG_CI_END="0.5990712698608415" LOG_CI_START="-0.4217391912131425" LOG_EFFECT_SIZE="0.08866603932384952" ORDER="26" O_E="0.0" SE="0.5996291179281358" STUDY_ID="STD-MRC-1974a" TOTAL_1="47" TOTAL_2="46" VAR="0.35955507906727413" WEIGHT="22.16958787304595"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.34610031729506" CI_END="3.0223623527346986" CI_START="0.578585796719148" DF="1" EFFECT_SIZE="1.3223826714801445" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="116" I2="57.37607669083172" ID="CMP-001.05.02" LOG_CI_END="0.4803465309359477" LOG_CI_START="-0.23763223173575485" LOG_EFFECT_SIZE="0.1213571496000964" NO="2" P_CHI2="0.1255970055086688" P_Z="0.5076059075255788" STUDIES="2" TAU2="0.0" TOTAL_1="132" TOTAL_2="130" WEIGHT="100.00000000000001" Z="0.6625701339619943">
<NAME>At 3 years</NAME>
<DICH_DATA CI_END="2.263576782107998" CI_START="0.24850051672475695" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="77" LOG_CI_END="0.35479523065377844" LOG_CI_START="-0.6046727038703783" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="27" O_E="0.0" SE="0.5635962141823636" STUDY_ID="STD-ICMR_x002f_MRC-1989" TOTAL_1="85" TOTAL_2="83" VAR="0.3176406926406926" WEIGHT="74.65703971119135"/>
<DICH_DATA CI_END="12.141361960950055" CI_START="0.745497509402058" EFFECT_SIZE="3.0085470085470085" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="39" LOG_CI_END="1.084267406586729" LOG_CI_START="-0.12755380312279038" LOG_EFFECT_SIZE="0.47835680173196937" ORDER="28" O_E="0.0" SE="0.7118297771951042" STUDY_ID="STD-MRC-1974a" TOTAL_1="47" TOTAL_2="47" VAR="0.5067016317016317" WEIGHT="25.34296028880867"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2004323416877245" CI_END="1.682859416073263" CI_START="0.36390032237348446" DF="1" EFFECT_SIZE="0.7825554830287206" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="104" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="0.22604783708469126" LOG_CI_START="-0.43901755967904793" LOG_EFFECT_SIZE="-0.10648486129717835" NO="3" P_CHI2="0.6543721085835342" P_Z="0.5302483340940654" STUDIES="2" TAU2="0.0" TOTAL_1="127" TOTAL_2="117" WEIGHT="100.0" Z="0.6276269794122352">
<NAME>At 5 years</NAME>
<DICH_DATA CI_END="1.8609365674152192" CI_START="0.2426649075025892" EFFECT_SIZE="0.672" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="75" LOG_CI_END="0.2697315698577682" LOG_CI_START="-0.6149930237501177" LOG_EFFECT_SIZE="-0.17263072694617473" ORDER="29" O_E="0.0" SE="0.5196916057426415" STUDY_ID="STD-ICMR_x002f_MRC-1989" TOTAL_1="82" TOTAL_2="82" VAR="0.2700793650793651" WEIGHT="61.19451697127938"/>
<DICH_DATA CI_END="3.0670621845064154" CI_START="0.29854334722231984" EFFECT_SIZE="0.9568965517241379" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="29" LOG_CI_END="0.4867225813669712" LOG_CI_START="-0.5249926022474934" LOG_EFFECT_SIZE="-0.019135010440261058" ORDER="30" O_E="0.0" SE="0.5942865069260646" STUDY_ID="STD-MRC-1974a" TOTAL_1="45" TOTAL_2="35" VAR="0.3531764523143833" WEIGHT="38.80548302872063"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.346441226540801" CI_START="0.5207446400839344" DF="0" EFFECT_SIZE="1.6685714285714286" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="70" I2="0.0" ID="CMP-001.05.04" LOG_CI_END="0.7280647969840618" LOG_CI_START="-0.28337519145981405" LOG_EFFECT_SIZE="0.22234480276212384" NO="4" P_CHI2="1.0" P_Z="0.3888429623679731" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="78" WEIGHT="100.0" Z="0.8617175720605916">
<NAME>At 10 years</NAME>
<DICH_DATA CI_END="5.346441226540801" CI_START="0.5207446400839344" EFFECT_SIZE="1.6685714285714286" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="70" LOG_CI_END="0.7280647969840618" LOG_CI_START="-0.28337519145981405" LOG_EFFECT_SIZE="0.22234480276212384" ORDER="31" O_E="0.0" SE="0.5941248559206226" STUDY_ID="STD-ICMR_x002f_MRC-1989" TOTAL_1="78" TOTAL_2="78" VAR="0.3529843444227006" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.9894741470541355" CI_END="4.792979351336093" CI_START="0.7354552545355433" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="1.877504154142006" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" I2="39.873423299101624" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.6806055580090818" LOG_CI_START="-0.13344374482555998" LOG_EFFECT_SIZE="0.27358090659176093" METHOD="MH" NO="6" P_CHI2="0.17256969096555996" P_Q="0.540378730782251" P_Z="0.18770915082173273" Q="0.37483882897796494" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="264" TOTAL_2="260" WEIGHT="200.0" Z="1.3173863595497444">
<NAME>Deaths from any cause</NAME>
<GROUP_LABEL_1>Chemo + surgery</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chemo+surg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chemotherapy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.60032989839555" CI_END="11.641838199445411" CI_START="0.6014210991151903" DF="1" EFFECT_SIZE="2.646062570241238" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="37.51288399956943" ID="CMP-001.06.01" LOG_CI_END="1.0660215590807693" LOG_CI_START="-0.22082134000576129" LOG_EFFECT_SIZE="0.42260010953750404" NO="1" P_CHI2="0.2058565171758474" P_Z="0.19798727292899368" STUDIES="2" TAU2="0.0" TOTAL_1="132" TOTAL_2="130" WEIGHT="100.0" Z="1.2873070910895925">
<NAME>At 18 months</NAME>
<DICH_DATA CI_END="174.00879867633967" CI_START="0.48862034231187745" EFFECT_SIZE="9.220858895705522" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.240571208742207" LOG_CI_START="-0.31102845637630644" LOG_EFFECT_SIZE="0.9647713761829504" ORDER="32" O_E="0.0" SE="1.4988222739126613" STUDY_ID="STD-ICMR_x002f_MRC-1989" TOTAL_1="85" TOTAL_2="83" VAR="2.2464682087767205" WEIGHT="20.022999921591175"/>
<DICH_DATA CI_END="7.411592011240002" CI_START="0.13492377865422928" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8699115045292258" LOG_CI_START="-0.8699115045292258" LOG_EFFECT_SIZE="0.0" ORDER="33" O_E="0.0" SE="1.021980647783726" STUDY_ID="STD-MRC-1974a" TOTAL_1="47" TOTAL_2="47" VAR="1.0444444444444443" WEIGHT="79.97700007840882"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.0730817304689504" CI_END="4.95455945191088" CI_START="0.42463331983646124" DF="1" EFFECT_SIZE="1.4504726913637618" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="67.45937506037626" ID="CMP-001.06.02" LOG_CI_END="0.6950050440664864" LOG_CI_START="-0.37198593091104026" LOG_EFFECT_SIZE="0.16150955657772306" NO="2" P_CHI2="0.07959869643357254" P_Z="0.5529427241574928" STUDIES="2" TAU2="0.0" TOTAL_1="132" TOTAL_2="130" WEIGHT="100.00000000000001" Z="0.5933563103624916">
<NAME>At 3 years</NAME>
<DICH_DATA CI_END="2.744157212361234" CI_START="0.08318459449407903" EFFECT_SIZE="0.4777777777777778" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.43840898841414533" LOG_CI_START="-1.079957096133622" LOG_EFFECT_SIZE="-0.32077405385973834" ORDER="34" O_E="0.0" SE="0.8918957540966941" STUDY_ID="STD-ICMR_x002f_MRC-1989" TOTAL_1="47" TOTAL_2="47" VAR="0.7954780361757107" WEIGHT="88.8746895920768"/>
<DICH_DATA CI_END="174.00879867633967" CI_START="0.48862034231187745" EFFECT_SIZE="9.220858895705522" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.240571208742207" LOG_CI_START="-0.31102845637630644" LOG_EFFECT_SIZE="0.9647713761829504" ORDER="35" O_E="0.0" SE="1.4988222739126613" STUDY_ID="STD-MRC-1974a" TOTAL_1="85" TOTAL_2="83" VAR="2.2464682087767205" WEIGHT="11.125310407923209"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.7447848990735233" CI_END="1.2714706469593777" CI_START="0.5038631914494976" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8004044340277667" ESTIMABLE="YES" EVENTS_1="424" EVENTS_2="420" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.10430633854970163" LOG_CI_START="-0.2976873668560921" LOG_EFFECT_SIZE="-0.09669051415319524" METHOD="MH" NO="7" P_CHI2="0.8401293638604401" P_Q="0.555251944307231" P_Z="0.3457575351556307" Q="2.083530205897032" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="469" TOTAL_2="455" WEIGHT="400.0" Z="0.9428502130182446">
<NAME>Regained activity level</NAME>
<GROUP_LABEL_1>Chemo + surgery</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chemotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chemo+surg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.030268011058971853" CI_END="1.6613641835051014" CI_START="0.2589098359690745" DF="1" EFFECT_SIZE="0.6558532825535002" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="122" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="0.2204648434990481" LOG_CI_START="-0.5868514504305151" LOG_EFFECT_SIZE="-0.18319330346573348" NO="1" P_CHI2="0.8618835413145397" P_Z="0.3737366217439383" STUDIES="2" TAU2="0.0" TOTAL_1="132" TOTAL_2="130" WEIGHT="100.0" Z="0.8894959254546668">
<NAME>At 18 months</NAME>
<DICH_DATA CI_END="1.969855460023986" CI_START="0.1932492953807432" EFFECT_SIZE="0.6169871794871795" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="78" LOG_CI_END="0.2944343605692318" LOG_CI_START="-0.7138820809170784" LOG_EFFECT_SIZE="-0.2097238601739233" ORDER="36" O_E="0.0" SE="0.5922900689759417" STUDY_ID="STD-ICMR_x002f_MRC-1989" TOTAL_1="85" TOTAL_2="83" VAR="0.35080752580752583" WEIGHT="66.48531011969531"/>
<DICH_DATA CI_END="3.470009650409723" CI_START="0.15481869499672618" EFFECT_SIZE="0.7329545454545454" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="44" LOG_CI_END="0.5403306826046671" LOG_CI_START="-0.8101765976344688" LOG_EFFECT_SIZE="-0.13492295751490088" ORDER="37" O_E="0.0" SE="0.7932946615313218" STUDY_ID="STD-MRC-1974a" TOTAL_1="47" TOTAL_2="47" VAR="0.6293164200140944" WEIGHT="33.51468988030468"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.09507144850575627" CI_END="1.5014100554841234" CI_START="0.2402633205609357" DF="1" EFFECT_SIZE="0.6006111599480933" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="122" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="0.17649932016673536" LOG_CI_START="-0.6193125250507119" LOG_EFFECT_SIZE="-0.22140660244198826" NO="2" P_CHI2="0.7578262522817028" P_Z="0.2754569480517818" STUDIES="2" TAU2="0.0" TOTAL_1="132" TOTAL_2="130" WEIGHT="100.0" Z="1.0905818236648714">
<NAME>At 3 years</NAME>
<DICH_DATA CI_END="1.6890755893412608" CI_START="0.1734777910372785" EFFECT_SIZE="0.5413105413105413" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="78" LOG_CI_END="0.2276490855089784" LOG_CI_START="-0.7607561165349686" LOG_EFFECT_SIZE="-0.2665535155129951" ORDER="38" O_E="0.0" SE="0.5805941083652727" STUDY_ID="STD-ICMR_x002f_MRC-1989" TOTAL_1="85" TOTAL_2="83" VAR="0.33708951866846604" WEIGHT="69.05688810749717"/>
<DICH_DATA CI_END="3.470009650409723" CI_START="0.15481869499672618" EFFECT_SIZE="0.7329545454545454" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="44" LOG_CI_END="0.5403306826046671" LOG_CI_START="-0.8101765976344688" LOG_EFFECT_SIZE="-0.13492295751490088" ORDER="39" O_E="0.0" SE="0.7932946615313218" STUDY_ID="STD-MRC-1974a" TOTAL_1="47" TOTAL_2="47" VAR="0.6293164200140944" WEIGHT="30.94311189250282"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5427906829310332" CI_END="1.8544564271104262" CI_START="0.35494711111757205" DF="1" EFFECT_SIZE="0.8113161846630819" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="106" I2="0.0" ID="CMP-001.07.03" LOG_CI_END="0.2682166334652132" LOG_CI_START="-0.4498363541589372" LOG_EFFECT_SIZE="-0.09080986034686206" NO="3" P_CHI2="0.46127856058976524" P_Z="0.6200773493082368" STUDIES="2" TAU2="0.0" TOTAL_1="127" TOTAL_2="117" WEIGHT="100.0" Z="0.49574072885585885">
<NAME>At 5 years</NAME>
<DICH_DATA CI_END="1.9198926906328924" CI_START="0.18791656648088786" EFFECT_SIZE="0.6006493506493507" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="77" LOG_CI_END="0.28327695517834556" LOG_CI_START="-0.7260349313732064" LOG_EFFECT_SIZE="-0.22137898809743045" ORDER="40" O_E="0.0" SE="0.5928747983347973" STUDY_ID="STD-ICMR_x002f_MRC-1989" TOTAL_1="82" TOTAL_2="82" VAR="0.35150052650052654" WEIGHT="59.68124788063751"/>
<DICH_DATA CI_END="3.7019452676134943" CI_START="0.3407592272035527" EFFECT_SIZE="1.1231527093596059" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="29" LOG_CI_END="0.5684299935230018" LOG_CI_START="-0.4675523753485201" LOG_EFFECT_SIZE="0.050438809087240855" ORDER="41" O_E="0.0" SE="0.6085411716705644" STUDY_ID="STD-MRC-1974a" TOTAL_1="45" TOTAL_2="35" VAR="0.37032235761818333" WEIGHT="40.3187521193625"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.346441226540801" CI_START="0.5207446400839344" DF="0" EFFECT_SIZE="1.6685714285714286" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="70" I2="0.0" ID="CMP-001.07.04" LOG_CI_END="0.7280647969840618" LOG_CI_START="-0.28337519145981405" LOG_EFFECT_SIZE="0.22234480276212384" NO="4" P_CHI2="1.0" P_Z="0.3888429623679731" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="78" WEIGHT="100.0" Z="0.8617175720605916">
<NAME>At 10 years</NAME>
<DICH_DATA CI_END="5.346441226540801" CI_START="0.5207446400839344" EFFECT_SIZE="1.6685714285714286" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="70" LOG_CI_END="0.7280647969840618" LOG_CI_START="-0.28337519145981405" LOG_EFFECT_SIZE="0.22234480276212384" ORDER="42" O_E="0.0" SE="0.5941248559206226" STUDY_ID="STD-ICMR_x002f_MRC-1989" TOTAL_1="78" TOTAL_2="78" VAR="0.3529843444227006" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.779273886493293" CI_END="1.0036516135452" CI_START="0.43033612283076267" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6571967316153363" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="81" I2="58.152638925921345" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.0015829871398781144" LOG_CI_START="-0.36619219728806535" LOG_EFFECT_SIZE="-0.1823046050740936" METHOD="MH" NO="8" P_CHI2="0.0916632037890367" P_Q="0.597935509365966" P_Z="0.05200507575502843" Q="0.2781209746403226" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="193" TOTAL_2="188" WEIGHT="200.0" Z="1.9430917326126866">
<NAME>Deterioration of bone loss</NAME>
<GROUP_LABEL_1>Chemo + surgery</GROUP_LABEL_1>
<GROUP_LABEL_2>Chemotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chemo+surg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chemotherapy</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0888252851099347" CI_START="0.30895682218294085" DF="0" EFFECT_SIZE="0.58" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="41" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="0.03695819766204296" LOG_CI_START="-0.5101022105361684" LOG_EFFECT_SIZE="-0.23657200643706275" NO="1" P_CHI2="1.0" P_Z="0.09004843432651603" STUDIES="1" TAU2="0.0" TOTAL_1="79" TOTAL_2="82" WEIGHT="100.0" Z="1.6951422746682214">
<NAME>At 3 years</NAME>
<DICH_DATA CI_END="1.0888252851099347" CI_START="0.30895682218294085" EFFECT_SIZE="0.58" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="41" LOG_CI_END="0.03695819766204296" LOG_CI_START="-0.5101022105361684" LOG_EFFECT_SIZE="-0.23657200643706275" ORDER="43" O_E="0.0" SE="0.3213459917683239" STUDY_ID="STD-ICMR_x002f_MRC-1989" TOTAL_1="79" TOTAL_2="82" VAR="0.1032632464255677" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.61038729973469" CI_END="1.2939224442297044" CI_START="0.41113864077472306" DF="1" EFFECT_SIZE="0.7293706293706294" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="40" I2="78.30984828416594" ID="CMP-001.08.02" LOG_CI_END="0.1119082461530181" LOG_CI_START="-0.3860117042300799" LOG_EFFECT_SIZE="-0.13705172903853094" NO="2" P_CHI2="0.03177891866013871" P_Z="0.2806080863699082" STUDIES="2" TAU2="0.0" TOTAL_1="114" TOTAL_2="106" WEIGHT="99.99999999999999" Z="1.0789543689815617">
<NAME>At 5 years</NAME>
<DICH_DATA CI_END="0.9933927935012806" CI_START="0.2654500116027401" EFFECT_SIZE="0.5135135135135135" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="37" LOG_CI_END="-0.002878994888389473" LOG_CI_START="-0.5760172513399427" LOG_EFFECT_SIZE="-0.28944812311416607" ORDER="44" O_E="0.0" SE="0.3366642489197676" STUDY_ID="STD-ICMR_x002f_MRC-1989" TOTAL_1="75" TOTAL_2="75" VAR="0.11334281650071124" WEIGHT="90.55944055944055"/>
<DICH_DATA CI_END="11.405520306729915" CI_START="0.6873864400008078" EFFECT_SIZE="2.8" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="1.0571151020797833" LOG_CI_START="-0.16279903939534507" LOG_EFFECT_SIZE="0.4471580313422192" ORDER="45" O_E="0.0" SE="0.7165836053748812" STUDY_ID="STD-MRC-1974a" TOTAL_1="39" TOTAL_2="31" VAR="0.5134920634920634" WEIGHT="9.44055944055944"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2008-11-09 09:48:31 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Lateral radiograph of the spine shows a kyphosis angle because two vertebral bodies were destroyed by tuberculosis; the bodies have fused, and further deterioration of the angle is unlikely. The angle is measured by drawing lines parallel to the healthy vertebral bodies above and below the fused bodies</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-02" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Lateral drawing of the spine illustrating the various levels</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAXEAAAJ5CAAAAAB9V1+IAACAAElEQVR42uydBzxV///4jz2y9yZ7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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-03" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Participant flow in MRC 1974a</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAkwAAAKpCAAAAABrhiwuAAATsklEQVR42u3di3KizBoF0P3+L+2p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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2008-11-09 09:48:31 +0000" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Participant flow in <LINK REF="STD-ICMR_x002f_MRC-1989" TYPE="STUDY">ICMR/MRC 1989</LINK>
</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAo0AAANOCAAAAABRzWk/AAAZk0lEQVR42u3dgXKjuhJF0fP/P82r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==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-11-09 13:02:33 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-11-09 09:49:46 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-11-09 09:49:20 +0000" MODIFIED_BY="[Empty name]">Search methods: detailed search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-09 09:49:46 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="6" ROWS="8">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Search set</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>CIDG SR<SUP>a</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>CENTRAL</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>MEDLINE<SUP>b</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>EMBASE<SUP>b</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>LILACS<SUP>b</SUP>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>tuberculosis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>TUBERCULOSIS SPINAL</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>TUBERCULOSIS, SPINAL</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>tuberculosis spondylitis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>spinal tuberculosis</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>spine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pott<SUP>a</SUP> disease</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>spinal tuberculosis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>TUBERCULOUS SPONDYLITIS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>TUBERCULOUS SPONDYLITIS tuberculous spondylitis</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 or 2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>tuberculous spondylitis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>spinal tuberculosis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pott's disease</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>spinal TB</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>spinal TB</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 or 2 or 3</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pott's disease</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>vertebral tuberculosis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pott's paraplegia</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pott's disease</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 or 2 or 3 or 4 or 5 or 6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 or 2 or 3 or 4 or 5 or 6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
</TABLE>
<P>
<SUP>a</SUP>Cochrane Infectious Diseases Group Specialized Register.<BR/>
<SUP>b</SUP>Search terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>); upper case: MeSH or EMTREE heading; lower case: free text term.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-11-09 12:57:10 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-11-09 12:56:51 +0000" MODIFIED_BY="[Empty name]">Characteristics of included participants</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-09 12:57:10 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="10">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Characteristic</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<LINK REF="STD-MRC-1974a" TYPE="STUDY">MRC 1974a</LINK>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<LINK REF="STD-ICMR_x002f_MRC-1989" TYPE="STUDY">ICMR/MRC 1989</LINK>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Number enrolled</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>130</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>201</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Number available at follow up</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 years: 94 (47 in each arm)<BR/>5 years: 80 (45 in surgical arm, and 35 in chemotherapy alone arm)<BR/>(some data available at 18 months)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 years: 168 (85 in surgical arm, and 83 in chemotherapy alone arm)<BR/>5 years: 164 (82 in each arm)<BR/>10 years: 156 (78 in each arm)<BR/>(some data available at 18 months)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Age</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Of the 94 people available for analysis at 3 years: 16 were &lt; 15 years and 78 &#8805; 15 years; age range not given</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Of the 168 people available for analysis at 3 years: 63 were &lt; 15 years; 105 &#8805; 15 years; age range not given</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Gender</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Of the 94 people available for analysis at 3 years 52 were male and 42 female</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not given</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Number vertebrae involved</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 or 2 in 70 participants<BR/>&gt; 2 in 24 participants</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 or 2 in 115 participants<BR/>&gt; 2 in 53 participants</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Location of lesions</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Thoracic (39 participants)<BR/>Thoracolumbar (10 participants)<BR/>Lumbar (45 participants)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Thoracic or thoracolumbar (84 participants)<BR/>Lumbar or lumbosacral (84 participants)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Kyphosis angle at entry</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27° (40 surgical group participants)<BR/>24° (33 chemotherapy group participants)<BR/>(standard deviation not provided)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Only provided for thoracic or thoracolumbar localization:<BR/>29° (mean in the surgical group)<BR/>29° (mean in the chemotherapy group)<BR/>(standard deviation not provided)<BR/>&gt; 20° in 66 of 84 patients with thoracic or thoracolumbar localizations</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mean total bone loss at start of treatment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.8 U (treatment group)<BR/>0.7 U (control group)<BR/>(standard deviation not provided)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.8 U (treatment group)<BR/>1.0 U (control group)<BR/>(standard deviation not provided)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Neurological deficit on entry</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12/94 participants<BR/>12 had incomplete paraplegia but were able to walk (inclusion criterion for this trial)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11/168 participants<BR/>11 had incomplete paraplegia but were able to walk (inclusion criterion for this trial)</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2008-11-09 12:58:50 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2008-11-09 12:58:44 +0000" MODIFIED_BY="[Empty name]">Risk of bias (methodological quality) of included studies<SUP>a</SUP>
</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-09 12:58:50 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="4" ROWS="3">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Trial</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Allocation sequence generation</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Allocation concealment</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Inclusion<SUP>b</SUP>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-MRC-1974a" TYPE="STUDY">MRC 1974a</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>Adequate</P>
</TD>
<TD VALIGN="TOP">
<P>Kyphosis angle and neurology: inadequate at 3 and 5 years follow up</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-ICMR_x002f_MRC-1989" TYPE="STUDY">ICMR/MRC 1989</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>Adequate</P>
</TD>
<TD VALIGN="TOP">
<P>Kyphosis angle: inadequate at 3, 5, and 10 years follow up</P>
<P>Neurology: adequate at 3 and 5 years follow up, and inadequate at 10 years follow up</P>
</TD>
</TR>
</TABLE>
<P>
<SUP>a</SUP>Details in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'.<BR/>
<SUP>b</SUP>Inclusion of all randomized (enrolled) participants in the analysis for primary outcomes.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2008-11-09 13:00:42 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2008-11-09 12:59:03 +0000" MODIFIED_BY="[Empty name]">Reasons for changing allocated treatment</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-09 13:00:42 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="5" ROWS="10">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Trial</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Intervention</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>No. participants</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Reason for change</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Details</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<LINK REF="STD-MRC-1974a" TYPE="STUDY">MRC 1974a</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Chemotherapy plus surgery</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Additional treatment needed</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Received extra chemotherapy for persistent sinus</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Chemotherapy</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Additional treatment needed</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Received extra chemotherapy for progressive neurological deficit</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Chemotherapy</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Randomization broken</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Needed decompression operation because of progressive neurological deficit</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<LINK REF="STD-ICMR_x002f_MRC-1989" TYPE="STUDY">ICMR/MRC 1989</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Chemotherapy plus surgery</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Additional treatment needed</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Bone graft displaced posteriorly and a second operation needed to remove the graft</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Chemotherapy plus surgery</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Additional treatment needed</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Developed myelopathy with complete paralysis immediately postoperative for which additional chemotherapy was added in third month</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Chemotherapy plus surgery</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Additional treatment needed</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Developed a sinus and graft infection that needed a second operation to remove graft</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Chemotherapy plus surgery</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Randomization broken</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Problem with exposure of lesion during operation, which had to be abandoned; both received chemotherapy as allocated</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Chemotherapy</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Randomization broken</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Needed decompression operation because of progressive neurological deficit</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Chemotherapy</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Randomization broken</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Developed abscesses that were treated with additional chemotherapy</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2008-11-09 13:01:08 +0000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2008-11-09 13:00:54 +0000" MODIFIED_BY="[Empty name]">Mean kyphosis angle (degrees)</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-09 13:01:08 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="5" ROWS="12">
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P/>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>
<LINK REF="STD-MRC-1974a" TYPE="STUDY">MRC 1974a</LINK>
</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>
<LINK REF="STD-ICMR_x002f_MRC-1989" TYPE="STUDY">ICMR/MRC 1989</LINK>
</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Chemotherapy plus surgery</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Chemotherapy alone</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Chemotherapy plus surgery</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Chemotherapy alone</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lesions</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>T1 to S1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>T1 to S1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>T1 to L2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>T1 to L2</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Angle at start</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27°</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>24°</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>29°</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>29°</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Angle at 18 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40°</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30°</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>41°</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>41°</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Angle at 3 years</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40°</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>32°</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>41°</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>42°</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Angle at 5 years</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>39°</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30°</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>37°</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40°</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Angle at 10 years</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>41°</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>47°</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Increase in angle at 18 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13° (40 participants)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6° (33 participants)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12° (34 participants)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12° (42 participants)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Increase in angle at 3 years</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13° (40 participants)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8° (33 participants)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12° (34 participants)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13° (42 participants)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Increase in angle at 5 years</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12° (34 participants)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6° (24 participants)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8° (34 participants)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11° (45 participants)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Increase in angle at 10 years</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12° (28 participants)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18° (41 participants)</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2008-11-09 13:01:36 +0000" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2008-11-09 13:01:26 +0000" MODIFIED_BY="[Empty name]">Deaths from any cause</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-09 13:01:36 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="6" ROWS="25">
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>Trial</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>Time of death</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>Cause of death</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Chemotherapy</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>Group not provided</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Plus surgery</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Alone</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="9" VALIGN="TOP">
<P>
<LINK REF="STD-MRC-1974a" TYPE="STUDY">MRC 1974a</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unknown, 60 years, 5 weeks after decompression surgery for progressive neurological deficit (change of allocated treatment)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cerebral haemorrhage</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pneumonia and dysentery</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Undiagnosed acute illness</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>23 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Heart failure in 24 year old</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>31 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sudden death from unknown cause, 53 years</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 to 5 years</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Stomach cancer</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 to 5 years</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unknown</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 to 5 years</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Heart failure</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="14" VALIGN="TOP">
<P>
<LINK REF="STD-ICMR_x002f_MRC-1989" TYPE="STUDY">ICMR/MRC 1989</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 month</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Died &lt; 24 h from disseminated coagulation disorder, woman 25 years</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 month</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Died &lt; 24 h from acute dilatation of the stomach, man 60 years</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 month</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Died from secondary haemorrhage four weeks postoperatively, woman 18 years</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Died in the 5th month of dyspnoea supposedly from a pulmonary embolism, woman 35 years</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&lt; 1 year</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Myocardial infarction</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&lt; 1 year</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Burn wounds</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&lt; 1 year</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Malignant disease</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&lt; 1 year</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Fall from height</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 to 2 years</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Encephalitis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 to 2 years</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unknown</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 to 3 years</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Viral infection</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 to 3 years</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pyrexia of unknown origin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 to 5 years</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unknown, nontuberculous</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5 to 10 years</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unknown, nontuberculous</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2008-11-09 13:02:14 +0000" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2008-11-09 13:02:01 +0000" MODIFIED_BY="[Empty name]">Bone loss (U)</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-09 13:02:14 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="7" ROWS="6">
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>Trial</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>Intervention</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>Fraction loss: start</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="3" VALIGN="BOTTOM">
<P>Deterioration</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>Total bone loss: 5 years</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>18 months</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>3 years</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>5 years</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-MRC-1974a" TYPE="STUDY">MRC 1974a</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Chemotherapy plus surgery</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Chemotherapy</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.7</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-ICMR_x002f_MRC-1989" TYPE="STUDY">ICMR/MRC 1989</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Chemotherapy plus surgery</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.1</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Chemotherapy</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.95</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.45</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-08" MODIFIED="2008-11-09 13:02:33 +0000" MODIFIED_BY="[Empty name]" NO="8">
<TITLE MODIFIED="2008-11-09 13:02:23 +0000" MODIFIED_BY="[Empty name]">Adverse events</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-09 13:02:33 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="4" ROWS="5">
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>Adverse event</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>Trial</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Chemotherapy</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Plus surgery</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Alone</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Operated on the wrong level (excision of healthy bone instead of diseased bone)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-ICMR_x002f_MRC-1989" TYPE="STUDY">ICMR/MRC 1989</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cases of hepatitis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>"</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Graft failure by breakage or displacement, in all these patients the graft spanned more than 3 disc spaces (at 10 year follow up)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>"</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>